CZ20023951A3 - Substituované bicyklické deriváty pro léčení abnormálního buničného růstu - Google Patents

Info

Publication number

CZ20023951A3

CZ20023951A3 CZ20023951A CZ20023951A CZ20023951A3 CZ 20023951 A3 CZ20023951 A3 CZ 20023951A3 CZ 20023951 A CZ20023951 A CZ 20023951A CZ 20023951 A CZ20023951 A CZ 20023951A CZ 20023951 A3 CZ20023951 A3 CZ 20023951A3

Authority

CZ

Czechia

Prior art keywords

yloxy

phenylamino

methyl

pyridin

quinazolin

Prior art date

2000-06-22

Links

• Espacenet
• Global Dossier
• Discuss

• 230000002159 abnormal effect Effects 0.000 title claims abstract description 35
• 230000010261 cell growth Effects 0.000 title claims abstract description 31
• 125000002619 bicyclic group Chemical group 0.000 title claims description 5
• 150000001875 compounds Chemical class 0.000 claims abstract description 147
• 238000000034 method Methods 0.000 claims abstract description 105
• 150000003839 salts Chemical class 0.000 claims abstract description 43
• 229940002612 prodrug Drugs 0.000 claims abstract description 27
• 239000000651 prodrug Substances 0.000 claims abstract description 27
• 241000124008 Mammalia Species 0.000 claims abstract description 18
• 239000012453 solvate Substances 0.000 claims abstract description 15
• 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 14
• -1 C 1 -C 6 alkoxy Chemical group 0.000 claims description 362
• 125000004547 quinazolin-6-yl group Chemical group N1=CN=CC2=CC(=CC=C12)* 0.000 claims description 63
• 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 62
• 206010028980 Neoplasm Diseases 0.000 claims description 41
• 125000000623 heterocyclic group Chemical group 0.000 claims description 36
• 239000003112 inhibitor Substances 0.000 claims description 28
• DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims description 27
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 27
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 26
• 125000004432 carbon atom Chemical group C* 0.000 claims description 26
• 229910052757 nitrogen Inorganic materials 0.000 claims description 23
• 125000003118 aryl group Chemical group 0.000 claims description 22
• 125000000217 alkyl group Chemical group 0.000 claims description 20
• 201000011510 cancer Diseases 0.000 claims description 16
• GCJFJAWCAZPMDN-UHFFFAOYSA-N 6-(3-aminoprop-1-ynyl)-n-[3-methyl-4-(6-methylpyridin-3-yl)oxyphenyl]quinazolin-4-amine Chemical compound C1=NC(C)=CC=C1OC(C(=C1)C)=CC=C1NC1=NC=NC2=CC=C(C#CCN)C=C12 GCJFJAWCAZPMDN-UHFFFAOYSA-N 0.000 claims description 15
• 125000004430 oxygen atom Chemical group O* 0.000 claims description 13
• 229910052736 halogen Inorganic materials 0.000 claims description 11
• 150000002367 halogens Chemical class 0.000 claims description 11
• 229910052739 hydrogen Inorganic materials 0.000 claims description 11
• 125000004433 nitrogen atom Chemical group N* 0.000 claims description 11
• 125000001424 substituent group Chemical group 0.000 claims description 11
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 10
• 229910052799 carbon Inorganic materials 0.000 claims description 9
• NUXRNLPBHAIASC-UHFFFAOYSA-N n-(3-methyl-4-pyridin-3-yloxyphenyl)-6-(2-piperidin-4-ylethynyl)quinazolin-4-amine Chemical compound C=1C=C(OC=2C=NC=CC=2)C(C)=CC=1NC(C1=C2)=NC=NC1=CC=C2C#CC1CCNCC1 NUXRNLPBHAIASC-UHFFFAOYSA-N 0.000 claims description 9
• 229910052717 sulfur Inorganic materials 0.000 claims description 9
• 125000004434 sulfur atom Chemical group 0.000 claims description 9
• 208000014829 head and neck neoplasm Diseases 0.000 claims description 8
• 239000001257 hydrogen Substances 0.000 claims description 8
• 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 8
• 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 8
• 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 8
• 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 8
• 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 8
• 125000003342 alkenyl group Chemical group 0.000 claims description 7
• 201000010099 disease Diseases 0.000 claims description 7
• 125000005843 halogen group Chemical group 0.000 claims description 7
• 229910052760 oxygen Inorganic materials 0.000 claims description 7
• 239000001301 oxygen Substances 0.000 claims description 7
• AFNJRWJHTHPHFY-UHFFFAOYSA-N 2-(dimethylamino)-n-[3-[4-(3-methyl-4-pyridin-3-yloxyanilino)quinazolin-6-yl]prop-2-ynyl]acetamide Chemical compound C12=CC(C#CCNC(=O)CN(C)C)=CC=C2N=CN=C1NC(C=C1C)=CC=C1OC1=CC=CN=C1 AFNJRWJHTHPHFY-UHFFFAOYSA-N 0.000 claims description 6
• 208000026310 Breast neoplasm Diseases 0.000 claims description 6
• 102000004190 Enzymes Human genes 0.000 claims description 6
• 108090000790 Enzymes Proteins 0.000 claims description 6
• 125000000304 alkynyl group Chemical group 0.000 claims description 6
• 210000003169 central nervous system Anatomy 0.000 claims description 6
• 125000004093 cyano group Chemical group *C#N 0.000 claims description 6
• 206010033128 Ovarian cancer Diseases 0.000 claims description 5
• 230000000340 anti-metabolite Effects 0.000 claims description 5
• 229940100197 antimetabolite Drugs 0.000 claims description 5
• 239000002256 antimetabolite Substances 0.000 claims description 5
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 5
• 150000001721 carbon Chemical group 0.000 claims description 5
• 239000003102 growth factor Substances 0.000 claims description 5
• 206010006187 Breast cancer Diseases 0.000 claims description 4
• 229940123587 Cell cycle inhibitor Drugs 0.000 claims description 4
• 206010061535 Ovarian neoplasm Diseases 0.000 claims description 4
• 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 4
• 208000015634 Rectal Neoplasms Diseases 0.000 claims description 4
• 206010039491 Sarcoma Diseases 0.000 claims description 4
• 208000005718 Stomach Neoplasms Diseases 0.000 claims description 4
• 208000024770 Thyroid neoplasm Diseases 0.000 claims description 4
• 125000003545 alkoxy group Chemical group 0.000 claims description 4
• 239000002168 alkylating agent Substances 0.000 claims description 4
• 229940100198 alkylating agent Drugs 0.000 claims description 4
• 230000002280 anti-androgenic effect Effects 0.000 claims description 4
• 230000003388 anti-hormonal effect Effects 0.000 claims description 4
• 239000000051 antiandrogen Substances 0.000 claims description 4
• 229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 claims description 4
• 239000002246 antineoplastic agent Substances 0.000 claims description 4
• 239000011203 carbon fibre reinforced carbon Substances 0.000 claims description 4
• 125000000753 cycloalkyl group Chemical group 0.000 claims description 4
• 231100000433 cytotoxic Toxicity 0.000 claims description 4
• 230000001472 cytotoxic effect Effects 0.000 claims description 4
• 239000003937 drug carrier Substances 0.000 claims description 4
• 206010017758 gastric cancer Diseases 0.000 claims description 4
• 210000003734 kidney Anatomy 0.000 claims description 4
• 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 4
• 201000001441 melanoma Diseases 0.000 claims description 4
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
• IZXNOTSZIXTRGF-UHFFFAOYSA-N n-[3-[4-[3-methyl-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-6-yl]prop-2-ynyl]acetamide Chemical compound C12=CC(C#CCNC(=O)C)=CC=C2N=CN=C1NC(C=C1C)=CC=C1OC1=CC=C(C)N=C1 IZXNOTSZIXTRGF-UHFFFAOYSA-N 0.000 claims description 4
• 201000002528 pancreatic cancer Diseases 0.000 claims description 4
• 208000008443 pancreatic carcinoma Diseases 0.000 claims description 4
• 125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 claims description 4
• 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 claims description 4
• 206010038038 rectal cancer Diseases 0.000 claims description 4
• 201000001275 rectum cancer Diseases 0.000 claims description 4
• 201000011549 stomach cancer Diseases 0.000 claims description 4
• CXSODTANAUJQKJ-UHFFFAOYSA-N 1-ethyl-3-[2-methyl-4-[4-[3-methyl-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-6-yl]but-3-yn-2-yl]urea Chemical compound C12=CC(C#CC(C)(C)NC(=O)NCC)=CC=C2N=CN=C1NC(C=C1C)=CC=C1OC1=CC=C(C)N=C1 CXSODTANAUJQKJ-UHFFFAOYSA-N 0.000 claims description 3
• FIHRYOGQFRGJTM-UHFFFAOYSA-N 1-ethyl-3-[3-[4-[3-methyl-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-6-yl]prop-2-ynyl]urea Chemical compound C12=CC(C#CCNC(=O)NCC)=CC=C2N=CN=C1NC(C=C1C)=CC=C1OC1=CC=C(C)N=C1 FIHRYOGQFRGJTM-UHFFFAOYSA-N 0.000 claims description 3
• ZYAJQMUTJUFTQJ-UHFFFAOYSA-N 2-methoxy-n-[1-[2-[4-[3-methyl-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-6-yl]ethynyl]cyclopropyl]acetamide Chemical compound C=1C=C2N=CN=C(NC=3C=C(C)C(OC=4C=NC(C)=CC=4)=CC=3)C2=CC=1C#CC1(NC(=O)COC)CC1 ZYAJQMUTJUFTQJ-UHFFFAOYSA-N 0.000 claims description 3
• QHRCOBHMIMIKJW-UHFFFAOYSA-N 2-methoxy-n-[3-[4-(3-methyl-4-pyridin-3-yloxyanilino)quinazolin-6-yl]prop-2-ynyl]acetamide Chemical compound C12=CC(C#CCNC(=O)COC)=CC=C2N=CN=C1NC(C=C1C)=CC=C1OC1=CC=CN=C1 QHRCOBHMIMIKJW-UHFFFAOYSA-N 0.000 claims description 3
• UZFMOKQJFYMBGY-UHFFFAOYSA-N 4-hydroxy-TEMPO Chemical compound CC1(C)CC(O)CC(C)(C)N1[O] UZFMOKQJFYMBGY-UHFFFAOYSA-N 0.000 claims description 3
• 206010000830 Acute leukaemia Diseases 0.000 claims description 3
• 206010005003 Bladder cancer Diseases 0.000 claims description 3
• 206010005949 Bone cancer Diseases 0.000 claims description 3
• 208000018084 Bone neoplasm Diseases 0.000 claims description 3
• 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 3
• LLVZBTWPGQVVLW-SNAWJCMRSA-N CP-724714 Chemical compound C12=CC(/C=C/CNC(=O)COC)=CC=C2N=CN=C1NC(C=C1C)=CC=C1OC1=CC=C(C)N=C1 LLVZBTWPGQVVLW-SNAWJCMRSA-N 0.000 claims description 3
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 3
• 206010007953 Central nervous system lymphoma Diseases 0.000 claims description 3
• 206010008342 Cervix carcinoma Diseases 0.000 claims description 3
• 208000001976 Endocrine Gland Neoplasms Diseases 0.000 claims description 3
• 206010014733 Endometrial cancer Diseases 0.000 claims description 3
• 206010014759 Endometrial neoplasm Diseases 0.000 claims description 3
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
• 206010061252 Intraocular melanoma Diseases 0.000 claims description 3
• 208000008839 Kidney Neoplasms Diseases 0.000 claims description 3
• 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
• 206010025323 Lymphomas Diseases 0.000 claims description 3
• 208000000821 Parathyroid Neoplasms Diseases 0.000 claims description 3
• 208000007913 Pituitary Neoplasms Diseases 0.000 claims description 3
• 201000005746 Pituitary adenoma Diseases 0.000 claims description 3
• 206010061538 Pituitary tumour benign Diseases 0.000 claims description 3
• 206010060862 Prostate cancer Diseases 0.000 claims description 3
• 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 3
• 206010038389 Renal cancer Diseases 0.000 claims description 3
• 208000006265 Renal cell carcinoma Diseases 0.000 claims description 3
• 208000000453 Skin Neoplasms Diseases 0.000 claims description 3
• 208000023915 Ureteral Neoplasms Diseases 0.000 claims description 3
• 206010046392 Ureteric cancer Diseases 0.000 claims description 3
• 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 3
• 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 3
• 208000002495 Uterine Neoplasms Diseases 0.000 claims description 3
• 201000005969 Uveal melanoma Diseases 0.000 claims description 3
• 208000004354 Vulvar Neoplasms Diseases 0.000 claims description 3
• 201000005188 adrenal gland cancer Diseases 0.000 claims description 3
• 208000024447 adrenal gland neoplasm Diseases 0.000 claims description 3
• 239000003242 anti bacterial agent Substances 0.000 claims description 3
• 229940088710 antibiotic agent Drugs 0.000 claims description 3
• 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 claims description 3
• 201000010881 cervical cancer Diseases 0.000 claims description 3
• 230000001684 chronic effect Effects 0.000 claims description 3
• 208000024207 chronic leukemia Diseases 0.000 claims description 3
• 208000029742 colonic neoplasm Diseases 0.000 claims description 3
• 208000030381 cutaneous melanoma Diseases 0.000 claims description 3
• 239000003534 dna topoisomerase inhibitor Substances 0.000 claims description 3
• 125000005842 heteroatom Chemical group 0.000 claims description 3
• 125000004356 hydroxy functional group Chemical group O* 0.000 claims description 3
• 239000000367 immunologic factor Substances 0.000 claims description 3
• 201000010982 kidney cancer Diseases 0.000 claims description 3
• 201000005202 lung cancer Diseases 0.000 claims description 3
• 208000020816 lung neoplasm Diseases 0.000 claims description 3
• 210000004698 lymphocyte Anatomy 0.000 claims description 3
• 208000029559 malignant endocrine neoplasm Diseases 0.000 claims description 3
• 208000020984 malignant renal pelvis neoplasm Diseases 0.000 claims description 3
• 208000026037 malignant tumor of neck Diseases 0.000 claims description 3
• 208000026045 malignant tumor of parathyroid gland Diseases 0.000 claims description 3
• HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical compound CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 claims description 3
• 230000000394 mitotic effect Effects 0.000 claims description 3
• HJDLJTQZLYROKJ-UHFFFAOYSA-N n-[3-methyl-4-(2-methylpyridin-3-yl)oxyphenyl]-6-(2-piperidin-4-ylethynyl)quinazolin-4-amine Chemical compound C=1C=C(OC=2C(=NC=CC=2)C)C(C)=CC=1NC(C1=C2)=NC=NC1=CC=C2C#CC1CCNCC1 HJDLJTQZLYROKJ-UHFFFAOYSA-N 0.000 claims description 3
• ZTNZMOQHMZZCBD-UHFFFAOYSA-N n-[3-methyl-4-(6-methylpyridin-3-yl)oxyphenyl]-6-(2-piperidin-4-ylethynyl)quinazolin-4-amine Chemical compound C1=NC(C)=CC=C1OC(C(=C1)C)=CC=C1NC1=NC=NC2=CC=C(C#CC3CCNCC3)C=C12 ZTNZMOQHMZZCBD-UHFFFAOYSA-N 0.000 claims description 3
• 201000002575 ocular melanoma Diseases 0.000 claims description 3
• 208000021310 pituitary gland adenoma Diseases 0.000 claims description 3
• 208000016800 primary central nervous system lymphoma Diseases 0.000 claims description 3
• 201000007444 renal pelvis carcinoma Diseases 0.000 claims description 3
• 201000000849 skin cancer Diseases 0.000 claims description 3
• 201000003708 skin melanoma Diseases 0.000 claims description 3
• 201000002314 small intestine cancer Diseases 0.000 claims description 3
• 201000002510 thyroid cancer Diseases 0.000 claims description 3
• 229940044693 topoisomerase inhibitor Drugs 0.000 claims description 3
• 201000011294 ureter cancer Diseases 0.000 claims description 3
• 201000005112 urinary bladder cancer Diseases 0.000 claims description 3
• 206010046766 uterine cancer Diseases 0.000 claims description 3
• 206010046885 vaginal cancer Diseases 0.000 claims description 3
• 208000013139 vaginal neoplasm Diseases 0.000 claims description 3
• 201000005102 vulva cancer Diseases 0.000 claims description 3
• MIIQJAUWHSUTIT-UHFFFAOYSA-N 1,2-oxazole-5-carboxylic acid Chemical compound OC(=O)C1=CC=NO1 MIIQJAUWHSUTIT-UHFFFAOYSA-N 0.000 claims description 2
• DKGVTDKLGNLAPO-UHFFFAOYSA-N 2-(hydroxymethyl)-n-[3-[4-[3-methyl-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-6-yl]prop-2-ynyl]pyrrolidine-1-carboxamide Chemical compound C1=NC(C)=CC=C1OC(C(=C1)C)=CC=C1NC1=NC=NC2=CC=C(C#CCNC(=O)N3C(CCC3)CO)C=C12 DKGVTDKLGNLAPO-UHFFFAOYSA-N 0.000 claims description 2
• ZTOIFVLFPSFAIL-UHFFFAOYSA-N 2-methoxy-n-[3-[4-[3-methyl-4-(2-methylpyridin-3-yl)oxyanilino]quinazolin-6-yl]prop-2-ynyl]acetamide Chemical compound C12=CC(C#CCNC(=O)COC)=CC=C2N=CN=C1NC(C=C1C)=CC=C1OC1=CC=CN=C1C ZTOIFVLFPSFAIL-UHFFFAOYSA-N 0.000 claims description 2
• BAVGSGLGSGTNSC-UHFFFAOYSA-N 2-methoxy-n-[3-[4-[3-methyl-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-6-yl]prop-2-ynyl]acetamide Chemical compound C12=CC(C#CCNC(=O)COC)=CC=C2N=CN=C1NC(C=C1C)=CC=C1OC1=CC=C(C)N=C1 BAVGSGLGSGTNSC-UHFFFAOYSA-N 0.000 claims description 2
• 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims description 2
• 206010006143 Brain stem glioma Diseases 0.000 claims description 2
• 206010009944 Colon cancer Diseases 0.000 claims description 2
• MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims description 2
• 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 2
• 208000021712 Soft tissue sarcoma Diseases 0.000 claims description 2
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 2
• 229940088598 enzyme Drugs 0.000 claims description 2
• 125000001434 methanylylidene group Chemical group [H]C#[*] 0.000 claims description 2
• 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims description 2
• PGNQYDWBJQHLKF-UHFFFAOYSA-N n-[3-[4-[3-chloro-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-6-yl]prop-2-ynyl]acetamide Chemical compound C12=CC(C#CCNC(=O)C)=CC=C2N=CN=C1NC(C=C1Cl)=CC=C1OC1=CC=C(C)N=C1 PGNQYDWBJQHLKF-UHFFFAOYSA-N 0.000 claims description 2
• RFIOZSIHFNEKFF-UHFFFAOYSA-N piperazine-1-carboxylic acid Chemical compound OC(=O)N1CCNCC1 RFIOZSIHFNEKFF-UHFFFAOYSA-N 0.000 claims description 2
• 239000011593 sulfur Substances 0.000 claims description 2
• 210000003101 oviduct Anatomy 0.000 claims 1
• 210000003899 penis Anatomy 0.000 claims 1
• 230000005855 radiation Effects 0.000 claims 1
• 125000006413 ring segment Chemical group 0.000 claims 1
• 206010062261 spinal cord neoplasm Diseases 0.000 claims 1
• 208000037959 spinal tumor Diseases 0.000 claims 1
• 230000002485 urinary effect Effects 0.000 claims 1
• 238000004128 high performance liquid chromatography Methods 0.000 description 43
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 39
• XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 37
• 150000001408 amides Chemical class 0.000 description 33
• 239000000243 solution Substances 0.000 description 32
• YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 27
• 239000000203 mixture Substances 0.000 description 24
• WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 22
• 208000035475 disorder Diseases 0.000 description 20
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 17
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 15
• 235000019439 ethyl acetate Nutrition 0.000 description 15
• 238000011282 treatment Methods 0.000 description 15
• HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 14
• 239000011541 reaction mixture Substances 0.000 description 14
• 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 13
• 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 13
• 230000015572 biosynthetic process Effects 0.000 description 13
• 239000002904 solvent Substances 0.000 description 13
• 238000003786 synthesis reaction Methods 0.000 description 13
• XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 12
• 239000003795 chemical substances by application Substances 0.000 description 12
• 238000006243 chemical reaction Methods 0.000 description 11
• WFKAJVHLWXSISD-UHFFFAOYSA-N isobutyramide Chemical compound CC(C)C(N)=O WFKAJVHLWXSISD-UHFFFAOYSA-N 0.000 description 11
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
• 239000002253 acid Substances 0.000 description 10
• 150000001412 amines Chemical class 0.000 description 10
• 229940080818 propionamide Drugs 0.000 description 10
• ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 9
• 239000002585 base Substances 0.000 description 9
• 239000004202 carbamide Substances 0.000 description 9
• 230000002401 inhibitory effect Effects 0.000 description 9
• 239000007787 solid Substances 0.000 description 9
• WGHUJVCIXUSOLP-UHFFFAOYSA-N 3-[4-(3-methyl-4-pyridin-3-yloxyanilino)quinazolin-6-yl]prop-2-en-1-ol Chemical compound CC1=CC(NC=2C3=CC(C=CCO)=CC=C3N=CN=2)=CC=C1OC1=CC=CN=C1 WGHUJVCIXUSOLP-UHFFFAOYSA-N 0.000 description 8
• 102000001301 EGF receptor Human genes 0.000 description 8
• 108060006698 EGF receptor Proteins 0.000 description 8
• KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 8
• 230000012010 growth Effects 0.000 description 8
• BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 8
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
• 125000004122 cyclic group Chemical group 0.000 description 7
• 239000000741 silica gel Substances 0.000 description 7
• 229910002027 silica gel Inorganic materials 0.000 description 7
• 239000000725 suspension Substances 0.000 description 7
• DJKQYUOLBRCGRQ-UHFFFAOYSA-N 2-chloro-n-[3-[4-(3-methyl-4-pyridin-3-yloxyanilino)quinazolin-6-yl]prop-2-ynyl]acetamide Chemical compound CC1=CC(NC=2C3=CC(=CC=C3N=CN=2)C#CCNC(=O)CCl)=CC=C1OC1=CC=CN=C1 DJKQYUOLBRCGRQ-UHFFFAOYSA-N 0.000 description 6
• WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
• YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
• ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
• 230000001594 aberrant effect Effects 0.000 description 6
• 230000004913 activation Effects 0.000 description 6
• 125000004429 atom Chemical group 0.000 description 6
• 239000012267 brine Substances 0.000 description 6
• 210000004027 cell Anatomy 0.000 description 6
• 239000000460 chlorine Substances 0.000 description 6
• UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 6
• 238000001704 evaporation Methods 0.000 description 6
• 229940047889 isobutyramide Drugs 0.000 description 6
• 239000000047 product Substances 0.000 description 6
• QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 description 6
• 108091008598 receptor tyrosine kinases Proteins 0.000 description 6
• 239000011734 sodium Substances 0.000 description 6
• HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 6
• 238000003756 stirring Methods 0.000 description 6
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
• HHKJGPXPBFCFMJ-UHFFFAOYSA-N 1-[3-[4-[3-chloro-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-6-yl]prop-2-ynyl]-3-methylurea Chemical compound C12=CC(C#CCNC(=O)NC)=CC=C2N=CN=C1NC(C=C1Cl)=CC=C1OC1=CC=C(C)N=C1 HHKJGPXPBFCFMJ-UHFFFAOYSA-N 0.000 description 5
• 108091000080 Phosphotransferase Proteins 0.000 description 5
• 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 5
• 101710100968 Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 5
• PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 5
• 150000007513 acids Chemical class 0.000 description 5
• 150000001345 alkine derivatives Chemical group 0.000 description 5
• 150000001732 carboxylic acid derivatives Chemical class 0.000 description 5
• 239000003153 chemical reaction reagent Substances 0.000 description 5
• 230000003211 malignant effect Effects 0.000 description 5
• 239000012044 organic layer Substances 0.000 description 5
• 102000020233 phosphotransferase Human genes 0.000 description 5
• 230000002062 proliferating effect Effects 0.000 description 5
• 150000003254 radicals Chemical class 0.000 description 5
• 102000027426 receptor tyrosine kinases Human genes 0.000 description 5
• 230000009467 reduction Effects 0.000 description 5
• 238000006722 reduction reaction Methods 0.000 description 5
• 150000003335 secondary amines Chemical class 0.000 description 5
• SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 4
• QPSSMWLYGSWBDR-UHFFFAOYSA-N 6-(3-aminoprop-1-ynyl)-n-[3-chloro-4-(6-methylpyridin-3-yl)oxyphenyl]quinazolin-4-amine Chemical compound C1=NC(C)=CC=C1OC(C(=C1)Cl)=CC=C1NC1=NC=NC2=CC=C(C#CCN)C=C12 QPSSMWLYGSWBDR-UHFFFAOYSA-N 0.000 description 4
• VHSPZKNNNJSZSN-NSCUHMNNSA-N 6-[(e)-3-aminoprop-1-enyl]-n-[3-chloro-4-(6-methylpyridin-3-yl)oxyphenyl]quinazolin-4-amine Chemical compound C1=NC(C)=CC=C1OC(C(=C1)Cl)=CC=C1NC1=NC=NC2=CC=C(\C=C\CN)C=C12 VHSPZKNNNJSZSN-NSCUHMNNSA-N 0.000 description 4
• 102100026802 72 kDa type IV collagenase Human genes 0.000 description 4
• HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 4
• VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 4
• 108010016165 Matrix Metalloproteinase 2 Proteins 0.000 description 4
• 102000001776 Matrix metalloproteinase-9 Human genes 0.000 description 4
• 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 4
• DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 4
• 230000002378 acidificating effect Effects 0.000 description 4
• 125000003277 amino group Chemical group 0.000 description 4
• 239000000908 ammonium hydroxide Substances 0.000 description 4
• 230000001028 anti-proliverative effect Effects 0.000 description 4
• 125000006615 aromatic heterocyclic group Chemical group 0.000 description 4
• 150000007514 bases Chemical class 0.000 description 4
• 150000001768 cations Chemical class 0.000 description 4
• 239000013058 crude material Substances 0.000 description 4
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
• 230000000694 effects Effects 0.000 description 4
• 230000008020 evaporation Effects 0.000 description 4
• 230000005764 inhibitory process Effects 0.000 description 4
• 239000010410 layer Substances 0.000 description 4
• 239000000463 material Substances 0.000 description 4
• 150000007522 mineralic acids Chemical class 0.000 description 4
• VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 4
• 150000007524 organic acids Chemical class 0.000 description 4
• 239000002953 phosphate buffered saline Substances 0.000 description 4
• 229910000027 potassium carbonate Inorganic materials 0.000 description 4
• 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
• YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
• 230000004614 tumor growth Effects 0.000 description 4
• 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 4
• 239000005483 tyrosine kinase inhibitor Substances 0.000 description 4
• NVQSYCZPMFWIJH-UHFFFAOYSA-N 2-chloro-n-[3-(4-chloroquinazolin-6-yl)prop-2-ynyl]acetamide Chemical compound N1=CN=C(Cl)C2=CC(C#CCNC(=O)CCl)=CC=C21 NVQSYCZPMFWIJH-UHFFFAOYSA-N 0.000 description 3
• CRTYFDUAZFWPDR-UHFFFAOYSA-N 6-(3-aminoprop-1-ynyl)-n-(3-methyl-4-pyridin-3-yloxyphenyl)quinazolin-4-amine Chemical compound CC1=CC(NC=2C3=CC(=CC=C3N=CN=2)C#CCN)=CC=C1OC1=CC=CN=C1 CRTYFDUAZFWPDR-UHFFFAOYSA-N 0.000 description 3
• PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 3
• 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 3
• UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
• RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical class CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
• XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 3
• 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 3
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
• 241001465754 Metazoa Species 0.000 description 3
• 108700020796 Oncogene Proteins 0.000 description 3
• 208000004403 Prostatic Hyperplasia Diseases 0.000 description 3
• 201000004681 Psoriasis Diseases 0.000 description 3
• 125000000066 S-methyl group Chemical group [H]C([H])([H])S* 0.000 description 3
• 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 3
• NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 3
• 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 3
• 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 3
• 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 3
• JEDZLBFUGJTJGQ-UHFFFAOYSA-N [Na].COCCO[AlH]OCCOC Chemical class [Na].COCCO[AlH]OCCOC JEDZLBFUGJTJGQ-UHFFFAOYSA-N 0.000 description 3
• 239000004480 active ingredient Substances 0.000 description 3
• 229910052783 alkali metal Inorganic materials 0.000 description 3
• 150000001340 alkali metals Chemical class 0.000 description 3
• 125000000539 amino acid group Chemical group 0.000 description 3
• 150000001413 amino acids Chemical class 0.000 description 3
• 230000001093 anti-cancer Effects 0.000 description 3
• 239000000872 buffer Substances 0.000 description 3
• 229910052801 chlorine Inorganic materials 0.000 description 3
• 238000004587 chromatography analysis Methods 0.000 description 3
• KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
• 238000010168 coupling process Methods 0.000 description 3
• YMGUBTXCNDTFJI-UHFFFAOYSA-N cyclopropanecarboxylic acid Chemical compound OC(=O)C1CC1 YMGUBTXCNDTFJI-UHFFFAOYSA-N 0.000 description 3
• 150000002148 esters Chemical class 0.000 description 3
• 229910052731 fluorine Inorganic materials 0.000 description 3
• 230000006870 function Effects 0.000 description 3
• 239000007789 gas Substances 0.000 description 3
• 238000011534 incubation Methods 0.000 description 3
• 238000002347 injection Methods 0.000 description 3
• 239000007924 injection Substances 0.000 description 3
• 230000003834 intracellular effect Effects 0.000 description 3
• 229910052740 iodine Inorganic materials 0.000 description 3
• 230000004048 modification Effects 0.000 description 3
• 238000012986 modification Methods 0.000 description 3
• 231100000252 nontoxic Toxicity 0.000 description 3
• 230000003000 nontoxic effect Effects 0.000 description 3
• 239000003960 organic solvent Substances 0.000 description 3
• 239000000546 pharmaceutical excipient Substances 0.000 description 3
• TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 3
• 239000002244 precipitate Substances 0.000 description 3
• 150000003141 primary amines Chemical class 0.000 description 3
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
• 108090000623 proteins and genes Proteins 0.000 description 3
• 230000002829 reductive effect Effects 0.000 description 3
• 230000002441 reversible effect Effects 0.000 description 3
• 229920006395 saturated elastomer Polymers 0.000 description 3
• 229910052708 sodium Inorganic materials 0.000 description 3
• 238000004611 spectroscopical analysis Methods 0.000 description 3
• 239000007858 starting material Substances 0.000 description 3
• 238000012360 testing method Methods 0.000 description 3
• 230000001225 therapeutic effect Effects 0.000 description 3
• 238000002560 therapeutic procedure Methods 0.000 description 3
• 125000001113 thiadiazolyl group Chemical group 0.000 description 3
• PAJPWUMXBYXFCZ-UHFFFAOYSA-N 1-aminocyclopropanecarboxylic acid Chemical compound OC(=O)C1(N)CC1 PAJPWUMXBYXFCZ-UHFFFAOYSA-N 0.000 description 2
• CAAQAOPBTSEEPE-UHFFFAOYSA-N 2-(hydroxymethyl)pyrrolidine-1-carboxylic acid Chemical compound OCC1CCCN1C(O)=O CAAQAOPBTSEEPE-UHFFFAOYSA-N 0.000 description 2
• NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 2
• HKXJUPUXPYJGBC-UHFFFAOYSA-N 2-fluoro-n-[3-[4-[3-methyl-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-6-yl]prop-2-ynyl]acetamide Chemical compound C1=NC(C)=CC=C1OC(C(=C1)C)=CC=C1NC1=NC=NC2=CC=C(C#CCNC(=O)CF)C=C12 HKXJUPUXPYJGBC-UHFFFAOYSA-N 0.000 description 2
• KXDYNPIASXTJGC-UHFFFAOYSA-N 3-[4-(3-methyl-4-pyridin-3-yloxyanilino)quinazolin-6-yl]prop-2-yn-1-ol Chemical compound CC1=CC(NC=2C3=CC(=CC=C3N=CN=2)C#CCO)=CC=C1OC1=CC=CN=C1 KXDYNPIASXTJGC-UHFFFAOYSA-N 0.000 description 2
• BDAIUOPDSRAOKI-UHFFFAOYSA-N 4-chloro-6-iodoquinazoline Chemical compound C1=C(I)C=C2C(Cl)=NC=NC2=C1 BDAIUOPDSRAOKI-UHFFFAOYSA-N 0.000 description 2
• KOVFKVAKBJGVGN-UHFFFAOYSA-N 6-(3-chloroprop-1-enyl)-n-(3-methyl-4-pyridin-3-yloxyphenyl)quinazolin-4-amine Chemical compound CC1=CC(NC=2C3=CC(C=CCCl)=CC=C3N=CN=2)=CC=C1OC1=CC=CN=C1 KOVFKVAKBJGVGN-UHFFFAOYSA-N 0.000 description 2
• 206010061424 Anal cancer Diseases 0.000 description 2
• 208000007860 Anus Neoplasms Diseases 0.000 description 2
• CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
• WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
• 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 2
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
• KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 2
• 239000004215 Carbon black (E152) Substances 0.000 description 2
• 201000009030 Carcinoma Diseases 0.000 description 2
• 108090000994 Catalytic RNA Proteins 0.000 description 2
• 102000053642 Catalytic RNA Human genes 0.000 description 2
• 241001227713 Chiron Species 0.000 description 2
• KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
• 229910021595 Copper(I) iodide Inorganic materials 0.000 description 2
• OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 2
• ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
• AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
• 102000009024 Epidermal Growth Factor Human genes 0.000 description 2
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
• 241000282412 Homo Species 0.000 description 2
• 208000037147 Hypercalcaemia Diseases 0.000 description 2
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
• FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
• TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
• 208000032271 Malignant tumor of penis Diseases 0.000 description 2
• 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 2
• 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 2
• AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
• BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
• YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
• 241000699670 Mus sp. Species 0.000 description 2
• LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
• 101150093908 PDGFRB gene Proteins 0.000 description 2
• 229910019142 PO4 Inorganic materials 0.000 description 2
• 208000002471 Penile Neoplasms Diseases 0.000 description 2
• 206010034299 Penile cancer Diseases 0.000 description 2
• ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
• 229920001213 Polysorbate 20 Polymers 0.000 description 2
• KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
• 229940124639 Selective inhibitor Drugs 0.000 description 2
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
• QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
• 206010046431 Urethral cancer Diseases 0.000 description 2
• 206010046458 Urethral neoplasms Diseases 0.000 description 2
• 238000002835 absorbance Methods 0.000 description 2
• 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
• 230000003213 activating effect Effects 0.000 description 2
• 125000004423 acyloxy group Chemical group 0.000 description 2
• 150000001298 alcohols Chemical class 0.000 description 2
• 150000001299 aldehydes Chemical class 0.000 description 2
• 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
• 125000005907 alkyl ester group Chemical group 0.000 description 2
• 239000004037 angiogenesis inhibitor Substances 0.000 description 2
• 201000011165 anus cancer Diseases 0.000 description 2
• 239000007864 aqueous solution Substances 0.000 description 2
• IADUEWIQBXOCDZ-UHFFFAOYSA-N azetidine-2-carboxylic acid Chemical compound OC(=O)C1CCN1 IADUEWIQBXOCDZ-UHFFFAOYSA-N 0.000 description 2
• 125000002393 azetidinyl group Chemical group 0.000 description 2
• UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 2
• 239000011230 binding agent Substances 0.000 description 2
• 230000000903 blocking effect Effects 0.000 description 2
• 239000011575 calcium Substances 0.000 description 2
• 229910052791 calcium Inorganic materials 0.000 description 2
• 230000000711 cancerogenic effect Effects 0.000 description 2
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
• 238000006555 catalytic reaction Methods 0.000 description 2
• 230000004663 cell proliferation Effects 0.000 description 2
• 125000001309 chloro group Chemical group Cl* 0.000 description 2
• 210000001072 colon Anatomy 0.000 description 2
• 239000003086 colorant Substances 0.000 description 2
• LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 2
• 230000008878 coupling Effects 0.000 description 2
• 238000005859 coupling reaction Methods 0.000 description 2
• 238000010511 deprotection reaction Methods 0.000 description 2
• 238000011161 development Methods 0.000 description 2
• 229940043279 diisopropylamine Drugs 0.000 description 2
• 239000002552 dosage form Substances 0.000 description 2
• 229940121647 egfr inhibitor Drugs 0.000 description 2
• 125000001033 ether group Chemical group 0.000 description 2
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
• 239000000284 extract Substances 0.000 description 2
• 239000000796 flavoring agent Substances 0.000 description 2
• 125000001153 fluoro group Chemical group F* 0.000 description 2
• 238000011010 flushing procedure Methods 0.000 description 2
• 235000013355 food flavoring agent Nutrition 0.000 description 2
• BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
• 230000014509 gene expression Effects 0.000 description 2
• RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
• 150000004820 halides Chemical class 0.000 description 2
• 229930195733 hydrocarbon Natural products 0.000 description 2
• 150000003840 hydrochlorides Chemical class 0.000 description 2
• 230000000148 hypercalcaemia Effects 0.000 description 2
• 208000030915 hypercalcemia disease Diseases 0.000 description 2
• 206010020718 hyperplasia Diseases 0.000 description 2
• 238000001727 in vivo Methods 0.000 description 2
• 208000015181 infectious disease Diseases 0.000 description 2
• 239000000543 intermediate Substances 0.000 description 2
• 201000002313 intestinal cancer Diseases 0.000 description 2
• 239000012948 isocyanate Substances 0.000 description 2
• 150000002513 isocyanates Chemical class 0.000 description 2
• 208000032839 leukemia Diseases 0.000 description 2
• 210000004072 lung Anatomy 0.000 description 2
• 239000011777 magnesium Substances 0.000 description 2
• 229910052749 magnesium Inorganic materials 0.000 description 2
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
• GTCAXTIRRLKXRU-UHFFFAOYSA-N methyl carbamate Chemical compound COC(N)=O GTCAXTIRRLKXRU-UHFFFAOYSA-N 0.000 description 2
• XSZGOIMTDYCGBX-UHFFFAOYSA-N n-[3-[4-(3-methyl-4-pyridin-3-yloxyanilino)quinazolin-6-yl]prop-2-ynyl]acetamide Chemical compound C12=CC(C#CCNC(=O)C)=CC=C2N=CN=C1NC(C=C1C)=CC=C1OC1=CC=CN=C1 XSZGOIMTDYCGBX-UHFFFAOYSA-N 0.000 description 2
• NRZMNEKBNBVFSJ-UHFFFAOYSA-N n-[3-methyl-4-(6-methylpyridin-3-yl)oxyphenyl]-6-(2-piperidin-3-ylethynyl)quinazolin-4-amine Chemical compound C1=NC(C)=CC=C1OC(C(=C1)C)=CC=C1NC1=NC=NC2=CC=C(C#CC3CNCCC3)C=C12 NRZMNEKBNBVFSJ-UHFFFAOYSA-N 0.000 description 2
• 235000005985 organic acids Nutrition 0.000 description 2
• 229910052763 palladium Inorganic materials 0.000 description 2
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
• 239000010452 phosphate Substances 0.000 description 2
• 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
• 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
• 159000000001 potassium salts Chemical class 0.000 description 2
• 239000002243 precursor Substances 0.000 description 2
• 238000002360 preparation method Methods 0.000 description 2
• 210000002307 prostate Anatomy 0.000 description 2
• 239000003528 protein farnesyltransferase inhibitor Substances 0.000 description 2
• 102000004169 proteins and genes Human genes 0.000 description 2
• 125000004546 quinazolin-4-yl group Chemical group N1=CN=C(C2=CC=CC=C12)* 0.000 description 2
• 125000002294 quinazolinyl group Chemical class N1=C(N=CC2=CC=CC=C12)* 0.000 description 2
• 102000005962 receptors Human genes 0.000 description 2
• 108020003175 receptors Proteins 0.000 description 2
• 238000006268 reductive amination reaction Methods 0.000 description 2
• 230000004044 response Effects 0.000 description 2
• 108091092562 ribozyme Proteins 0.000 description 2
• 239000012419 sodium bis(2-methoxyethoxy)aluminum hydride Substances 0.000 description 2
• 238000007920 subcutaneous administration Methods 0.000 description 2
• 239000000126 substance Substances 0.000 description 2
• 239000000758 substrate Substances 0.000 description 2
• 229940124530 sulfonamide Drugs 0.000 description 2
• 150000003456 sulfonamides Chemical class 0.000 description 2
• YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 2
• 239000003826 tablet Substances 0.000 description 2
• GWLXBNARWVFSHT-UHFFFAOYSA-N tert-butyl n-[3-[4-[3-methyl-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-6-yl]prop-2-ynyl]carbamate Chemical compound C1=NC(C)=CC=C1OC(C(=C1)C)=CC=C1NC1=NC=NC2=CC=C(C#CCNC(=O)OC(C)(C)C)C=C12 GWLXBNARWVFSHT-UHFFFAOYSA-N 0.000 description 2
• 125000000335 thiazolyl group Chemical group 0.000 description 2
• FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
• JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
• VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
• RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
• 210000004881 tumor cell Anatomy 0.000 description 2
• 238000003828 vacuum filtration Methods 0.000 description 2
• NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 2
• 239000002525 vasculotropin inhibitor Substances 0.000 description 2
• 239000011534 wash buffer Substances 0.000 description 2
• OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
• RBTCRFLJLUNCLL-UHFFFAOYSA-N (1-chloro-2-methyl-1-oxopropan-2-yl) acetate Chemical compound CC(=O)OC(C)(C)C(Cl)=O RBTCRFLJLUNCLL-UHFFFAOYSA-N 0.000 description 1
• FANZBPRWZWTATE-RUZDIDTESA-N (2R)-N-[3-[4-(3-methyl-4-pyridin-3-yloxyanilino)quinazolin-6-yl]prop-2-ynyl]pyrrolidine-2-carboxamide Chemical compound CC1=C(OC2=CC=CN=C2)C=CC(NC2=NC=NC3=CC=C(C=C23)C#CCNC(=O)[C@H]2CCCN2)=C1 FANZBPRWZWTATE-RUZDIDTESA-N 0.000 description 1
• ZKCAYXBXQSGFNN-AREMUKBSSA-N (2R)-N-[3-[4-[3-methyl-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-6-yl]prop-2-ynyl]pyrrolidine-2-carboxamide Chemical compound CC1=CC=C(OC2=C(C)C=C(NC3=NC=NC4=CC=C(C=C34)C#CCNC(=O)[C@H]3CCCN3)C=C2)C=N1 ZKCAYXBXQSGFNN-AREMUKBSSA-N 0.000 description 1
• LTVIJEFEZVFIST-AZUAARDMSA-N (2r,3r)-1-[4-[(2-chloro-4-fluorophenyl)methoxy]phenyl]sulfonyl-n,3-dihydroxy-3-methylpiperidine-2-carboxamide Chemical compound ONC(=O)[C@H]1[C@](C)(O)CCCN1S(=O)(=O)C(C=C1)=CC=C1OCC1=CC=C(F)C=C1Cl LTVIJEFEZVFIST-AZUAARDMSA-N 0.000 description 1
• ZHCXOELPVFPGHI-PZJWPPBQSA-N (2r,3r)-1-[4-[(4-fluoro-2-methylphenyl)methoxy]phenyl]sulfonyl-n,3-dihydroxy-3-methylpiperidine-2-carboxamide Chemical compound CC1=CC(F)=CC=C1COC1=CC=C(S(=O)(=O)N2[C@H]([C@](C)(O)CCC2)C(=O)NO)C=C1 ZHCXOELPVFPGHI-PZJWPPBQSA-N 0.000 description 1
• QOTHZZZSSJMAME-WDSKDSINSA-N (2s,5s)-2,5-dimethylpyrrolidine-1-carboxylic acid Chemical compound C[C@H]1CC[C@H](C)N1C(O)=O QOTHZZZSSJMAME-WDSKDSINSA-N 0.000 description 1
• RYWGPCLTVXMMHO-UHFFFAOYSA-N (4-chlorophenyl) carbonochloridate Chemical compound ClC(=O)OC1=CC=C(Cl)C=C1 RYWGPCLTVXMMHO-UHFFFAOYSA-N 0.000 description 1
• KMPLYESDOZJASB-PAHRJMAXSA-N (6s,8r,9s,10r,13s,14s,17r)-17-acetyl-17-hydroxy-6-methoxy-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1h-cyclopenta[a]phenanthren-3-one;(z)-n-carbamoyl-2-ethylbut-2-enamide;6-ethoxy-1,3-benzothiazole-2-sulfonamide Chemical compound CC\C(=C\C)C(=O)NC(N)=O.CCOC1=CC=C2N=C(S(N)(=O)=O)SC2=C1.C([C@@]12C)CC(=O)C=C1[C@@H](OC)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](O)(C(C)=O)CC[C@H]21 KMPLYESDOZJASB-PAHRJMAXSA-N 0.000 description 1
• 125000000008 (C1-C10) alkyl group Chemical group 0.000 description 1
• 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 1
• 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
• GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 1
• CHPRFKYDQRKRRK-LURJTMIESA-N (S)-2-(methoxymethyl)pyrrolidine Chemical compound COC[C@@H]1CCCN1 CHPRFKYDQRKRRK-LURJTMIESA-N 0.000 description 1
• RDMXDURNMNLMTL-NSCUHMNNSA-N (e)-3-[4-(3-chloro-4-pyridin-3-yloxyanilino)quinazolin-6-yl]prop-2-en-1-ol Chemical compound C12=CC(/C=C/CO)=CC=C2N=CN=C1NC(C=C1Cl)=CC=C1OC1=CC=CN=C1 RDMXDURNMNLMTL-NSCUHMNNSA-N 0.000 description 1
• WGHUJVCIXUSOLP-ONEGZZNKSA-N (e)-3-[4-(3-methyl-4-pyridin-3-yloxyanilino)quinazolin-6-yl]prop-2-en-1-ol Chemical compound CC1=CC(NC=2C3=CC(\C=C\CO)=CC=C3N=CN=2)=CC=C1OC1=CC=CN=C1 WGHUJVCIXUSOLP-ONEGZZNKSA-N 0.000 description 1
• JMYUEJNQKXNAII-ONEGZZNKSA-N (e)-3-[4-[3-methyl-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-6-yl]prop-2-en-1-ol Chemical compound C1=NC(C)=CC=C1OC(C(=C1)C)=CC=C1NC1=NC=NC2=CC=C(\C=C\CO)C=C12 JMYUEJNQKXNAII-ONEGZZNKSA-N 0.000 description 1
• UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 description 1
• YRSIJQKOJPEWCI-UHFFFAOYSA-N 1,1,3-trimethyl-3-[3-[4-[3-methyl-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-6-yl]prop-2-ynyl]urea Chemical compound C12=CC(C#CCN(C)C(=O)N(C)C)=CC=C2N=CN=C1NC(C=C1C)=CC=C1OC1=CC=C(C)N=C1 YRSIJQKOJPEWCI-UHFFFAOYSA-N 0.000 description 1
• RHTBONYMVPPQAS-UHFFFAOYSA-N 1,1-dimethyl-3-[3-[4-[3-methyl-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-6-yl]prop-2-ynyl]urea Chemical compound C12=CC(C#CCNC(=O)N(C)C)=CC=C2N=CN=C1NC(C=C1C)=CC=C1OC1=CC=C(C)N=C1 RHTBONYMVPPQAS-UHFFFAOYSA-N 0.000 description 1
• WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
• IRHPBASBTDHHGC-UHFFFAOYSA-N 1,3-dimethyl-1-[3-[4-[3-methyl-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-6-yl]prop-2-ynyl]urea Chemical compound C12=CC(C#CCN(C)C(=O)NC)=CC=C2N=CN=C1NC(C=C1C)=CC=C1OC1=CC=C(C)N=C1 IRHPBASBTDHHGC-UHFFFAOYSA-N 0.000 description 1
• JPRPJUMQRZTTED-UHFFFAOYSA-N 1,3-dioxolanyl Chemical group [CH]1OCCO1 JPRPJUMQRZTTED-UHFFFAOYSA-N 0.000 description 1
• JZLWSLYVRDHUFZ-UHFFFAOYSA-N 1-(1-hydroxybutan-2-yl)-3-[3-[4-[3-methyl-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-6-yl]prop-2-ynyl]urea Chemical compound C12=CC(C#CCNC(=O)NC(CO)CC)=CC=C2N=CN=C1NC(C=C1C)=CC=C1OC1=CC=C(C)N=C1 JZLWSLYVRDHUFZ-UHFFFAOYSA-N 0.000 description 1
• NNYKSHCMDWWJFJ-UHFFFAOYSA-N 1-(2-chloroethyl)-3-[3-[4-(3-methyl-4-pyridin-3-yloxyanilino)quinazolin-6-yl]prop-2-ynyl]urea Chemical compound CC1=CC(NC=2C3=CC(=CC=C3N=CN=2)C#CCNC(=O)NCCCl)=CC=C1OC1=CC=CN=C1 NNYKSHCMDWWJFJ-UHFFFAOYSA-N 0.000 description 1
• RGBDMTGVYQQLCK-UHFFFAOYSA-N 1-(2-methoxyethyl)-1-methyl-3-[3-[4-[3-methyl-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-6-yl]prop-2-ynyl]urea Chemical compound C12=CC(C#CCNC(=O)N(C)CCOC)=CC=C2N=CN=C1NC(C=C1C)=CC=C1OC1=CC=C(C)N=C1 RGBDMTGVYQQLCK-UHFFFAOYSA-N 0.000 description 1
• ABZLRNASKFAOIB-UHFFFAOYSA-N 1-(cyanomethyl)-3-[3-[4-[3-methyl-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-6-yl]prop-2-ynyl]urea Chemical compound C(#N)CNC(=O)NCC#CC=1C=C2C(=NC=NC2=CC=1)NC1=CC(=C(C=C1)OC=1C=NC(=CC=1)C)C ABZLRNASKFAOIB-UHFFFAOYSA-N 0.000 description 1
• NJHKBFZDLVOZHQ-UHFFFAOYSA-N 1-[3-[4-(3-chloro-4-pyridin-3-yloxyanilino)quinazolin-6-yl]prop-2-ynyl]-3-ethylurea Chemical compound C12=CC(C#CCNC(=O)NCC)=CC=C2N=CN=C1NC(C=C1Cl)=CC=C1OC1=CC=CN=C1 NJHKBFZDLVOZHQ-UHFFFAOYSA-N 0.000 description 1
• IUMXMWSJMBPNKY-UHFFFAOYSA-N 1-[3-[4-(3-methyl-4-pyridin-3-yloxyanilino)quinazolin-6-yl]prop-2-ynyl]-3-phenylurea Chemical compound C=1C=C(OC=2C=NC=CC=2)C(C)=CC=1NC(C1=C2)=NC=NC1=CC=C2C#CCNC(=O)NC1=CC=CC=C1 IUMXMWSJMBPNKY-UHFFFAOYSA-N 0.000 description 1
• WMXCTDYUHDSYHA-UHFFFAOYSA-N 1-[3-[4-[3-chloro-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-6-yl]prop-2-ynyl]-1,3,3-trimethylurea Chemical compound C12=CC(C#CCN(C)C(=O)N(C)C)=CC=C2N=CN=C1NC(C=C1Cl)=CC=C1OC1=CC=C(C)N=C1 WMXCTDYUHDSYHA-UHFFFAOYSA-N 0.000 description 1
• BQCWIZTVTXMAHH-UHFFFAOYSA-N 1-[3-[4-[3-chloro-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-6-yl]prop-2-ynyl]-3-(1-hydroxybutan-2-yl)urea Chemical compound C12=CC(C#CCNC(=O)NC(CO)CC)=CC=C2N=CN=C1NC(C=C1Cl)=CC=C1OC1=CC=C(C)N=C1 BQCWIZTVTXMAHH-UHFFFAOYSA-N 0.000 description 1
• QDHVKGQWQUEKBG-UHFFFAOYSA-N 1-[3-[4-[3-chloro-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-6-yl]prop-2-ynyl]-3-(2,2,2-trifluoroethyl)urea Chemical compound C1=NC(C)=CC=C1OC(C(=C1)Cl)=CC=C1NC1=NC=NC2=CC=C(C#CCNC(=O)NCC(F)(F)F)C=C12 QDHVKGQWQUEKBG-UHFFFAOYSA-N 0.000 description 1
• NUHYAVQUXMFOTG-UHFFFAOYSA-N 1-[3-[4-[3-chloro-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-6-yl]prop-2-ynyl]-3-(2-fluoroethyl)urea Chemical compound C1=NC(C)=CC=C1OC(C(=C1)Cl)=CC=C1NC1=NC=NC2=CC=C(C#CCNC(=O)NCCF)C=C12 NUHYAVQUXMFOTG-UHFFFAOYSA-N 0.000 description 1
• GSCHMCDKBQLMSP-UHFFFAOYSA-N 1-[3-[4-[3-chloro-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-6-yl]prop-2-ynyl]-3-(2-hydroxyethyl)urea Chemical compound C1=NC(C)=CC=C1OC(C(=C1)Cl)=CC=C1NC1=NC=NC2=CC=C(C#CCNC(=O)NCCO)C=C12 GSCHMCDKBQLMSP-UHFFFAOYSA-N 0.000 description 1
• QOCLRNDHMBJMNK-UHFFFAOYSA-N 1-[3-[4-[3-chloro-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-6-yl]prop-2-ynyl]-3-(3-methylbutan-2-yl)urea Chemical compound C12=CC(C#CCNC(=O)NC(C)C(C)C)=CC=C2N=CN=C1NC(C=C1Cl)=CC=C1OC1=CC=C(C)N=C1 QOCLRNDHMBJMNK-UHFFFAOYSA-N 0.000 description 1
• UMEVUNHCGAHGAY-UHFFFAOYSA-N 1-[3-[4-[3-chloro-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-6-yl]prop-2-ynyl]-3-cyclopropylurea Chemical compound C1=NC(C)=CC=C1OC(C(=C1)Cl)=CC=C1NC1=NC=NC2=CC=C(C#CCNC(=O)NC3CC3)C=C12 UMEVUNHCGAHGAY-UHFFFAOYSA-N 0.000 description 1
• FYIJNZMLVZOAIM-UHFFFAOYSA-N 1-[3-[4-[3-chloro-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-6-yl]prop-2-ynyl]-3-ethylurea Chemical compound C12=CC(C#CCNC(=O)NCC)=CC=C2N=CN=C1NC(C=C1Cl)=CC=C1OC1=CC=C(C)N=C1 FYIJNZMLVZOAIM-UHFFFAOYSA-N 0.000 description 1
• JFPMGNJZJFUJTL-UHFFFAOYSA-N 1-[3-[4-[3-chloro-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-6-yl]prop-2-ynyl]-3-propan-2-ylurea Chemical compound C12=CC(C#CCNC(=O)NC(C)C)=CC=C2N=CN=C1NC(C=C1Cl)=CC=C1OC1=CC=C(C)N=C1 JFPMGNJZJFUJTL-UHFFFAOYSA-N 0.000 description 1
• DZYQVPBEWHDANR-UHFFFAOYSA-N 1-[3-[4-[3-chloro-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-6-yl]prop-2-ynyl]-3-propylurea Chemical compound C12=CC(C#CCNC(=O)NCCC)=CC=C2N=CN=C1NC(C=C1Cl)=CC=C1OC1=CC=C(C)N=C1 DZYQVPBEWHDANR-UHFFFAOYSA-N 0.000 description 1
• XHOQGZQAFHLONS-UHFFFAOYSA-N 1-[3-[4-[3-methyl-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-6-yl]prop-2-ynyl]-3-pentan-3-ylurea Chemical compound C12=CC(C#CCNC(=O)NC(CC)CC)=CC=C2N=CN=C1NC(C=C1C)=CC=C1OC1=CC=C(C)N=C1 XHOQGZQAFHLONS-UHFFFAOYSA-N 0.000 description 1
• UCCGTTGQKMOHPY-UHFFFAOYSA-N 1-[3-[4-[3-methyl-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-6-yl]prop-2-ynyl]-3-propan-2-ylurea Chemical compound C12=CC(C#CCNC(=O)NC(C)C)=CC=C2N=CN=C1NC(C=C1C)=CC=C1OC1=CC=C(C)N=C1 UCCGTTGQKMOHPY-UHFFFAOYSA-N 0.000 description 1
• XEXHBHZXSRIAHU-UHFFFAOYSA-N 1-butan-2-yl-3-[3-[4-[3-chloro-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-6-yl]prop-2-ynyl]urea Chemical compound C12=CC(C#CCNC(=O)NC(C)CC)=CC=C2N=CN=C1NC(C=C1Cl)=CC=C1OC1=CC=C(C)N=C1 XEXHBHZXSRIAHU-UHFFFAOYSA-N 0.000 description 1
• AMDBKFZWZUUKJL-UHFFFAOYSA-N 1-butan-2-yl-3-[3-[4-[3-methyl-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-6-yl]prop-2-ynyl]urea Chemical compound C12=CC(C#CCNC(=O)NC(C)CC)=CC=C2N=CN=C1NC(C=C1C)=CC=C1OC1=CC=C(C)N=C1 AMDBKFZWZUUKJL-UHFFFAOYSA-N 0.000 description 1
• 125000004972 1-butynyl group Chemical group [H]C([H])([H])C([H])([H])C#C* 0.000 description 1
• KMAXOROIBKCWGQ-UHFFFAOYSA-N 1-cyclobutyl-3-[3-[4-[3-methyl-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-6-yl]prop-2-ynyl]urea Chemical compound C1=NC(C)=CC=C1OC(C(=C1)C)=CC=C1NC1=NC=NC2=CC=C(C#CCNC(=O)NC3CCC3)C=C12 KMAXOROIBKCWGQ-UHFFFAOYSA-N 0.000 description 1
• WJFIRJMFCLEOQV-UHFFFAOYSA-N 1-cyclohexyl-3-[3-[4-(3-methyl-4-pyridin-3-yloxyanilino)quinazolin-6-yl]prop-2-ynyl]urea Chemical compound C=1C=C(OC=2C=NC=CC=2)C(C)=CC=1NC(C1=C2)=NC=NC1=CC=C2C#CCNC(=O)NC1CCCCC1 WJFIRJMFCLEOQV-UHFFFAOYSA-N 0.000 description 1
• RGLZEPVFMKCDQW-UHFFFAOYSA-N 1-ethyl-1-(2-hydroxyethyl)-3-[3-[4-[3-methyl-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-6-yl]prop-2-ynyl]urea Chemical compound C12=CC(C#CCNC(=O)N(CCO)CC)=CC=C2N=CN=C1NC(C=C1C)=CC=C1OC1=CC=C(C)N=C1 RGLZEPVFMKCDQW-UHFFFAOYSA-N 0.000 description 1
• DMIGZUMIYIOOGZ-UHFFFAOYSA-N 1-ethyl-1-(2-hydroxyethyl)-3-[4-[4-[3-methyl-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-6-yl]but-3-yn-2-yl]urea Chemical compound C12=CC(C#CC(C)NC(=O)N(CCO)CC)=CC=C2N=CN=C1NC(C=C1C)=CC=C1OC1=CC=C(C)N=C1 DMIGZUMIYIOOGZ-UHFFFAOYSA-N 0.000 description 1
• DSAZJKQNMBINCA-UHFFFAOYSA-N 1-ethyl-3-[1-[2-[4-[3-methyl-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-6-yl]ethyl]cyclopropyl]urea Chemical compound C=1C=C2N=CN=C(NC=3C=C(C)C(OC=4C=NC(C)=CC=4)=CC=3)C2=CC=1CCC1(NC(=O)NCC)CC1 DSAZJKQNMBINCA-UHFFFAOYSA-N 0.000 description 1
• DMZAKXPWDAYNJE-UHFFFAOYSA-N 1-ethyl-3-[1-[2-[4-[3-methyl-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-6-yl]ethynyl]cyclopropyl]urea Chemical compound C=1C=C2N=CN=C(NC=3C=C(C)C(OC=4C=NC(C)=CC=4)=CC=3)C2=CC=1C#CC1(NC(=O)NCC)CC1 DMZAKXPWDAYNJE-UHFFFAOYSA-N 0.000 description 1
• GMSMFWNCTZQEJR-UHFFFAOYSA-N 1-ethyl-3-[3-[4-(3-methyl-4-pyridin-3-yloxyanilino)quinazolin-6-yl]prop-2-ynyl]urea Chemical compound C12=CC(C#CCNC(=O)NCC)=CC=C2N=CN=C1NC(C=C1C)=CC=C1OC1=CC=CN=C1 GMSMFWNCTZQEJR-UHFFFAOYSA-N 0.000 description 1
• CLELNQCUHBVKKO-UHFFFAOYSA-N 1-hydroxy-N-[3-[4-[3-methyl-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-6-yl]prop-2-ynyl]cyclopropane-1-carboxamide Chemical compound CC=1C=C(C=CC=1OC=1C=NC(=CC=1)C)NC1=NC=NC2=CC=C(C=C12)C#CCNC(=O)C1(CC1)O CLELNQCUHBVKKO-UHFFFAOYSA-N 0.000 description 1
• VNOWOUUMBMEBBQ-UHFFFAOYSA-N 1-methyl-3-[3-[4-[3-methyl-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-6-yl]prop-2-ynyl]-1-(2-methylpropyl)urea Chemical compound C12=CC(C#CCNC(=O)N(C)CC(C)C)=CC=C2N=CN=C1NC(C=C1C)=CC=C1OC1=CC=C(C)N=C1 VNOWOUUMBMEBBQ-UHFFFAOYSA-N 0.000 description 1
• YIRLBFNRLQGSRK-UHFFFAOYSA-N 1-methyl-4-[2-[4-(3-methyl-4-pyridin-3-yloxyanilino)quinazolin-6-yl]ethynyl]piperidin-4-ol Chemical compound C1CN(C)CCC1(O)C#CC1=CC=C(N=CN=C2NC=3C=C(C)C(OC=4C=NC=CC=4)=CC=3)C2=C1 YIRLBFNRLQGSRK-UHFFFAOYSA-N 0.000 description 1
• 125000001462 1-pyrrolyl group Chemical group [*]N1C([H])=C([H])C([H])=C1[H] 0.000 description 1
• YJOUGIBSOOWFTA-UHFFFAOYSA-N 1-tert-butyl-3-[3-[4-[3-chloro-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-6-yl]prop-2-ynyl]urea Chemical compound C1=NC(C)=CC=C1OC(C(=C1)Cl)=CC=C1NC1=NC=NC2=CC=C(C#CCNC(=O)NC(C)(C)C)C=C12 YJOUGIBSOOWFTA-UHFFFAOYSA-N 0.000 description 1
• WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 1
• ZZSRVBJBINETOA-UHFFFAOYSA-N 2-(dimethylamino)-n-[3-[4-[3-methyl-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-6-yl]prop-2-ynyl]acetamide Chemical compound C12=CC(C#CCNC(=O)CN(C)C)=CC=C2N=CN=C1NC(C=C1C)=CC=C1OC1=CC=C(C)N=C1 ZZSRVBJBINETOA-UHFFFAOYSA-N 0.000 description 1
• AWBQWIOQKWTQOW-UHFFFAOYSA-N 2-(methoxymethyl)pyrrolidine-1-carboxylic acid Chemical compound COCC1CCCN1C(O)=O AWBQWIOQKWTQOW-UHFFFAOYSA-N 0.000 description 1
• GUCMMDLUFIOSEC-UHFFFAOYSA-N 2-(methylamino)-n-[3-[4-[3-methyl-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-6-yl]prop-2-ynyl]acetamide Chemical compound C12=CC(C#CCNC(=O)CNC)=CC=C2N=CN=C1NC(C=C1C)=CC=C1OC1=CC=C(C)N=C1 GUCMMDLUFIOSEC-UHFFFAOYSA-N 0.000 description 1
• JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
• VKUYLANQOAKALN-UHFFFAOYSA-N 2-[benzyl-(4-methoxyphenyl)sulfonylamino]-n-hydroxy-4-methylpentanamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N(C(CC(C)C)C(=O)NO)CC1=CC=CC=C1 VKUYLANQOAKALN-UHFFFAOYSA-N 0.000 description 1
• HXLOGOSOYYXKCZ-UHFFFAOYSA-N 2-chloro-n-prop-2-ynylacetamide Chemical compound ClCC(=O)NCC#C HXLOGOSOYYXKCZ-UHFFFAOYSA-N 0.000 description 1
• AVRBELBDSSXATE-UHFFFAOYSA-N 2-cyano-n-[3-[4-[3-methyl-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-6-yl]prop-2-ynyl]acetamide Chemical compound C1=NC(C)=CC=C1OC(C(=C1)C)=CC=C1NC1=NC=NC2=CC=C(C#CCNC(=O)CC#N)C=C12 AVRBELBDSSXATE-UHFFFAOYSA-N 0.000 description 1
• FHQXDOQENHNLHS-UHFFFAOYSA-N 2-ethoxy-n-[3-[4-[3-methyl-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-6-yl]prop-2-ynyl]acetamide Chemical compound C12=CC(C#CCNC(=O)COCC)=CC=C2N=CN=C1NC(C=C1C)=CC=C1OC1=CC=C(C)N=C1 FHQXDOQENHNLHS-UHFFFAOYSA-N 0.000 description 1
• 125000004791 2-fluoroethoxy group Chemical group FCCO* 0.000 description 1
• 125000004777 2-fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 description 1
• MXDSOTQDGQVHLA-UHFFFAOYSA-N 2-hydroxy-2-methyl-n-[3-[4-[3-methyl-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-6-yl]prop-2-ynyl]propanamide Chemical compound C1=NC(C)=CC=C1OC(C(=C1)C)=CC=C1NC1=NC=NC2=CC=C(C#CCNC(=O)C(C)(C)O)C=C12 MXDSOTQDGQVHLA-UHFFFAOYSA-N 0.000 description 1
• NOOMSABOGFKNBI-UHFFFAOYSA-N 2-hydroxy-n-[2-methyl-4-[4-[3-methyl-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-6-yl]but-3-yn-2-yl]acetamide Chemical compound C1=NC(C)=CC=C1OC(C(=C1)C)=CC=C1NC1=NC=NC2=CC=C(C#CC(C)(C)NC(=O)CO)C=C12 NOOMSABOGFKNBI-UHFFFAOYSA-N 0.000 description 1
• JOGOPBBOTNARAQ-UHFFFAOYSA-N 2-hydroxy-n-[4-[4-(3-methyl-4-pyridin-3-yloxyanilino)quinazolin-6-yl]but-3-ynyl]acetamide Chemical compound CC1=CC(NC=2C3=CC(=CC=C3N=CN=2)C#CCCNC(=O)CO)=CC=C1OC1=CC=CN=C1 JOGOPBBOTNARAQ-UHFFFAOYSA-N 0.000 description 1
• LLVZBTWPGQVVLW-UHFFFAOYSA-N 2-methoxy-N-[3-[4-[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]anilino]-6-quinazolinyl]prop-2-enyl]acetamide Chemical compound C12=CC(C=CCNC(=O)COC)=CC=C2N=CN=C1NC(C=C1C)=CC=C1OC1=CC=C(C)N=C1 LLVZBTWPGQVVLW-UHFFFAOYSA-N 0.000 description 1
• OTSRKTDUOFZIIR-UHFFFAOYSA-N 2-methoxy-n-[3-[4-(3-methoxy-4-pyridin-3-yloxyanilino)quinazolin-6-yl]prop-2-ynyl]acetamide Chemical compound C12=CC(C#CCNC(=O)COC)=CC=C2N=CN=C1NC(C=C1OC)=CC=C1OC1=CC=CN=C1 OTSRKTDUOFZIIR-UHFFFAOYSA-N 0.000 description 1
• OJJORRYDBMMBOE-UHFFFAOYSA-N 2-methoxy-n-[3-[4-(3-methyl-4-pyridin-4-yloxyanilino)quinazolin-6-yl]prop-2-ynyl]acetamide Chemical compound C12=CC(C#CCNC(=O)COC)=CC=C2N=CN=C1NC(C=C1C)=CC=C1OC1=CC=NC=C1 OJJORRYDBMMBOE-UHFFFAOYSA-N 0.000 description 1
• VDWUKEOXAYLSEC-UHFFFAOYSA-N 2-methoxy-n-[3-[4-(4-pyridin-2-yloxyanilino)quinazolin-6-yl]prop-2-ynyl]acetamide Chemical compound C12=CC(C#CCNC(=O)COC)=CC=C2N=CN=C1NC(C=C1)=CC=C1OC1=CC=CC=N1 VDWUKEOXAYLSEC-UHFFFAOYSA-N 0.000 description 1
• DEIOMTULLSHYBV-UHFFFAOYSA-N 2-methoxy-n-[3-[4-[3-methyl-4-(2-methylpyrimidin-5-yl)oxyanilino]quinazolin-6-yl]prop-2-ynyl]acetamide Chemical compound C12=CC(C#CCNC(=O)COC)=CC=C2N=CN=C1NC(C=C1C)=CC=C1OC1=CN=C(C)N=C1 DEIOMTULLSHYBV-UHFFFAOYSA-N 0.000 description 1
• GULROODISOIXTN-UHFFFAOYSA-N 2-methoxy-n-[3-[4-[3-methyl-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-6-yl]prop-2-ynyl]propanamide Chemical compound C12=CC(C#CCNC(=O)C(C)OC)=CC=C2N=CN=C1NC(C=C1C)=CC=C1OC1=CC=C(C)N=C1 GULROODISOIXTN-UHFFFAOYSA-N 0.000 description 1
• IHMNNJDXAKRBTB-UHFFFAOYSA-N 2-methoxy-n-[3-[4-[4-(2-methylpyridin-3-yl)oxyanilino]quinazolin-6-yl]prop-2-ynyl]acetamide Chemical compound C12=CC(C#CCNC(=O)COC)=CC=C2N=CN=C1NC(C=C1)=CC=C1OC1=CC=CN=C1C IHMNNJDXAKRBTB-UHFFFAOYSA-N 0.000 description 1
• RXHTXEBUOBWFCG-UHFFFAOYSA-N 2-methoxy-n-[3-[7-methoxy-4-[3-methyl-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-6-yl]prop-2-ynyl]acetamide Chemical compound N1=CN=C2C=C(OC)C(C#CCNC(=O)COC)=CC2=C1NC(C=C1C)=CC=C1OC1=CC=C(C)N=C1 RXHTXEBUOBWFCG-UHFFFAOYSA-N 0.000 description 1
• KHHZATHAHLTCEO-UHFFFAOYSA-N 2-methoxy-n-[4-[4-(3-methyl-4-pyridin-3-yloxyanilino)quinazolin-6-yl]but-3-yn-2-yl]acetamide Chemical compound C12=CC(C#CC(C)NC(=O)COC)=CC=C2N=CN=C1NC(C=C1C)=CC=C1OC1=CC=CN=C1 KHHZATHAHLTCEO-UHFFFAOYSA-N 0.000 description 1
• VPRJDHIFEDMVSM-UHFFFAOYSA-N 2-methyl-4-[4-(3-methyl-4-pyridin-3-yloxyanilino)quinazolin-6-yl]but-3-yn-2-ol Chemical compound CC1=CC(NC=2C3=CC(=CC=C3N=CN=2)C#CC(C)(C)O)=CC=C1OC1=CC=CN=C1 VPRJDHIFEDMVSM-UHFFFAOYSA-N 0.000 description 1
• NOCKXTRFRWAAOP-UHFFFAOYSA-N 2-methyl-n-[3-[4-(3-methyl-4-pyridin-3-yloxyanilino)quinazolin-6-yl]prop-2-ynyl]propanamide Chemical compound C12=CC(C#CCNC(=O)C(C)C)=CC=C2N=CN=C1NC(C=C1C)=CC=C1OC1=CC=CN=C1 NOCKXTRFRWAAOP-UHFFFAOYSA-N 0.000 description 1
• DQKNCYKHRRTRFM-UHFFFAOYSA-N 2-methyl-n-[3-[4-(3-methyl-4-pyrimidin-5-yloxyanilino)quinazolin-6-yl]prop-2-ynyl]propanamide Chemical compound C12=CC(C#CCNC(=O)C(C)C)=CC=C2N=CN=C1NC(C=C1C)=CC=C1OC1=CN=CN=C1 DQKNCYKHRRTRFM-UHFFFAOYSA-N 0.000 description 1
• OVUWGANMOQIFHZ-UHFFFAOYSA-N 2-methylbutan-2-ylurea Chemical compound CCC(C)(C)NC(N)=O OVUWGANMOQIFHZ-UHFFFAOYSA-N 0.000 description 1
• NJNCCNWXWJZBDF-UHFFFAOYSA-N 2-methylpiperidine-1-carboxylic acid Chemical compound CC1CCCCN1C(O)=O NJNCCNWXWJZBDF-UHFFFAOYSA-N 0.000 description 1
• 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
• 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
• QNGKVLXQQAUJSV-UHFFFAOYSA-N 3-(dimethylamino)pyrrolidine-1-carboxylic acid Chemical compound CN(C)C1CCN(C(O)=O)C1 QNGKVLXQQAUJSV-UHFFFAOYSA-N 0.000 description 1
• ALKYHXVLJMQRLQ-UHFFFAOYSA-N 3-Hydroxy-2-naphthoate Chemical compound C1=CC=C2C=C(O)C(C(=O)O)=CC2=C1 ALKYHXVLJMQRLQ-UHFFFAOYSA-N 0.000 description 1
• BRMWTNUJHUMWMS-UHFFFAOYSA-N 3-Methylhistidine Natural products CN1C=NC(CC(N)C(O)=O)=C1 BRMWTNUJHUMWMS-UHFFFAOYSA-N 0.000 description 1
• NHFDRBXTEDBWCZ-ZROIWOOFSA-N 3-[2,4-dimethyl-5-[(z)-(2-oxo-1h-indol-3-ylidene)methyl]-1h-pyrrol-3-yl]propanoic acid Chemical compound OC(=O)CCC1=C(C)NC(\C=C/2C3=CC=CC=C3NC\2=O)=C1C NHFDRBXTEDBWCZ-ZROIWOOFSA-N 0.000 description 1
• YQQHBGVRXRPBTB-UHFFFAOYSA-N 3-[3-[4-[3-chloro-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-6-yl]prop-2-ynyl]-1,1-diethylurea Chemical compound C12=CC(C#CCNC(=O)N(CC)CC)=CC=C2N=CN=C1NC(C=C1Cl)=CC=C1OC1=CC=C(C)N=C1 YQQHBGVRXRPBTB-UHFFFAOYSA-N 0.000 description 1
• WFJZUYXGKANTHG-UHFFFAOYSA-N 3-[3-[4-[3-chloro-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-6-yl]prop-2-ynyl]-1,1-dimethylurea Chemical compound C12=CC(C#CCNC(=O)N(C)C)=CC=C2N=CN=C1NC(C=C1Cl)=CC=C1OC1=CC=C(C)N=C1 WFJZUYXGKANTHG-UHFFFAOYSA-N 0.000 description 1
• PHJKQDFOVWSLSN-UHFFFAOYSA-N 3-[3-[4-[3-chloro-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-6-yl]prop-2-ynyl]-1-(2-methoxyethyl)-1-methylurea Chemical compound C12=CC(C#CCNC(=O)N(C)CCOC)=CC=C2N=CN=C1NC(C=C1Cl)=CC=C1OC1=CC=C(C)N=C1 PHJKQDFOVWSLSN-UHFFFAOYSA-N 0.000 description 1
• ZZDCZJCKMODACE-UHFFFAOYSA-N 3-[3-[4-[3-chloro-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-6-yl]prop-2-ynyl]-1-ethyl-1-(2-hydroxyethyl)urea Chemical compound C12=CC(C#CCNC(=O)N(CCO)CC)=CC=C2N=CN=C1NC(C=C1Cl)=CC=C1OC1=CC=C(C)N=C1 ZZDCZJCKMODACE-UHFFFAOYSA-N 0.000 description 1
• ACNAJAMQFUJQFV-UHFFFAOYSA-N 3-[3-[7-methoxy-4-[3-methyl-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-6-yl]prop-2-ynyl]-1,1-di(propan-2-yl)urea Chemical compound C=12C=C(C#CCNC(=O)N(C(C)C)C(C)C)C(OC)=CC2=NC=NC=1NC(C=C1C)=CC=C1OC1=CC=C(C)N=C1 ACNAJAMQFUJQFV-UHFFFAOYSA-N 0.000 description 1
• CBEGZOIFDMJFLQ-UHFFFAOYSA-N 3-[4-(3-chloro-4-pyridin-3-yloxyanilino)quinazolin-6-yl]prop-2-yn-1-ol Chemical compound C12=CC(C#CCO)=CC=C2N=CN=C1NC(C=C1Cl)=CC=C1OC1=CC=CN=C1 CBEGZOIFDMJFLQ-UHFFFAOYSA-N 0.000 description 1
• DLEIMJIZBWJQFV-UHFFFAOYSA-N 3-[4-(3-methyl-4-pyridin-3-yloxyanilino)quinazolin-6-yl]prop-2-ynylcarbamothioic S-acid Chemical compound CC=1C=C(C=CC=1OC=1C=NC=CC=1)NC1=NC=NC2=CC=C(C=C12)C#CCNC(O)=S DLEIMJIZBWJQFV-UHFFFAOYSA-N 0.000 description 1
• NXADEHCTEKYMJB-UHFFFAOYSA-N 3-[4-[3-methyl-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-6-yl]prop-2-yn-1-ol Chemical compound C1=NC(C)=CC=C1OC(C(=C1)C)=CC=C1NC1=NC=NC2=CC=C(C#CCO)C=C12 NXADEHCTEKYMJB-UHFFFAOYSA-N 0.000 description 1
• DQVZYUGZZRKDBR-UHFFFAOYSA-N 3-[4-[3-methyl-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-6-yl]prop-2-ynylcarbamothioic S-acid Chemical compound CC=1C=C(C=CC=1OC=1C=NC(=CC=1)C)NC1=NC=NC2=CC=C(C=C12)C#CCNC(O)=S DQVZYUGZZRKDBR-UHFFFAOYSA-N 0.000 description 1
• BVNMNEWUDLSUOK-UHFFFAOYSA-N 3-[4-[3-methyl-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-6-yl]prop-2-ynylurea Chemical compound C1=NC(C)=CC=C1OC(C(=C1)C)=CC=C1NC1=NC=NC2=CC=C(C#CCNC(N)=O)C=C12 BVNMNEWUDLSUOK-UHFFFAOYSA-N 0.000 description 1
• JJSAEDOMTCNEQL-UHFFFAOYSA-N 3-[[4-(4-chlorophenoxy)phenyl]sulfonylamino]-n-hydroxyoxane-3-carboxamide Chemical compound C=1C=C(OC=2C=CC(Cl)=CC=2)C=CC=1S(=O)(=O)NC1(C(=O)NO)CCCOC1 JJSAEDOMTCNEQL-UHFFFAOYSA-N 0.000 description 1
• NMDUJEUWNLCXSB-UHFFFAOYSA-N 3-[[4-(4-fluorophenoxy)phenyl]sulfonyl-[1-(hydroxyamino)-2-methyl-1-oxopropan-2-yl]amino]propanoic acid Chemical compound C1=CC(S(=O)(=O)N(CCC(O)=O)C(C)(C)C(=O)NO)=CC=C1OC1=CC=C(F)C=C1 NMDUJEUWNLCXSB-UHFFFAOYSA-N 0.000 description 1
• PDCBVHDMAFCHPK-UHFFFAOYSA-N 3-[[4-(4-fluorophenoxy)phenyl]sulfonyl-[1-(hydroxycarbamoyl)cyclobutyl]amino]propanoic acid Chemical compound C=1C=C(OC=2C=CC(F)=CC=2)C=CC=1S(=O)(=O)N(CCC(O)=O)C1(C(=O)NO)CCC1 PDCBVHDMAFCHPK-UHFFFAOYSA-N 0.000 description 1
• WARXYAHFCARUNH-UHFFFAOYSA-N 3-[[4-(4-fluorophenoxy)phenyl]sulfonyl-[4-(hydroxycarbamoyl)oxan-4-yl]amino]propanoic acid Chemical compound C=1C=C(OC=2C=CC(F)=CC=2)C=CC=1S(=O)(=O)N(CCC(O)=O)C1(C(=O)NO)CCOCC1 WARXYAHFCARUNH-UHFFFAOYSA-N 0.000 description 1
• YZIGEYGKVJNXSU-UHFFFAOYSA-N 3-[[4-(4-fluorophenoxy)phenyl]sulfonylamino]-n-hydroxyoxolane-3-carboxamide Chemical compound C=1C=C(OC=2C=CC(F)=CC=2)C=CC=1S(=O)(=O)NC1(C(=O)NO)CCOC1 YZIGEYGKVJNXSU-UHFFFAOYSA-N 0.000 description 1
• FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical compound OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 description 1
• YZGYKWJZOBALKZ-UHFFFAOYSA-N 3-hydroxypyrrolidine-1-carboxylic acid Chemical compound OC1CCN(C(O)=O)C1 YZGYKWJZOBALKZ-UHFFFAOYSA-N 0.000 description 1
• OGUNWQBVMSDHJJ-UHFFFAOYSA-N 3-methoxyazetidine-1-carboxylic acid Chemical compound COC1CN(C(O)=O)C1 OGUNWQBVMSDHJJ-UHFFFAOYSA-N 0.000 description 1
• HXIYCKAAQPHZBM-UHFFFAOYSA-N 3-methyl-1,2-oxazole-5-carboxylic acid Chemical compound CC=1C=C(C(O)=O)ON=1 HXIYCKAAQPHZBM-UHFFFAOYSA-N 0.000 description 1
• UAQLILFDDXPFIB-UHFFFAOYSA-N 3-methyl-4-pyridin-3-yloxyaniline Chemical compound CC1=CC(N)=CC=C1OC1=CC=CN=C1 UAQLILFDDXPFIB-UHFFFAOYSA-N 0.000 description 1
• 125000003542 3-methylbutan-2-yl group Chemical group [H]C([H])([H])C([H])(*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• LMHIBYREWJHKNZ-UHFFFAOYSA-N 3-methylpyridine-2-carboxylic acid Chemical compound CC1=CC=CN=C1C(O)=O LMHIBYREWJHKNZ-UHFFFAOYSA-N 0.000 description 1
• 125000004364 3-pyrrolinyl group Chemical group [H]C1=C([H])C([H])([H])N(*)C1([H])[H] 0.000 description 1
• 125000001397 3-pyrrolyl group Chemical group [H]N1C([H])=C([*])C([H])=C1[H] 0.000 description 1
• UPMLOUAZCHDJJD-UHFFFAOYSA-N 4,4'-Diphenylmethane Diisocyanate Chemical compound C1=CC(N=C=O)=CC=C1CC1=CC=C(N=C=O)C=C1 UPMLOUAZCHDJJD-UHFFFAOYSA-N 0.000 description 1
• YKYWTRWMBZPHRP-UHFFFAOYSA-N 4,4-dimethyl-5-[2-[4-(3-methyl-4-pyridin-3-yloxyanilino)quinazolin-6-yl]ethynyl]-1,3-oxazolidin-2-one Chemical compound CC1(NC(OC1C#CC=1C=C2C(=NC=NC2=CC=1)NC1=CC(=C(C=C1)OC=1C=NC=CC=1)C)=O)C YKYWTRWMBZPHRP-UHFFFAOYSA-N 0.000 description 1
• MYOQDKDWYZIYFU-UHFFFAOYSA-N 4-[2-[4-(3-methyl-4-pyridin-3-yloxyanilino)quinazolin-6-yl]ethynyl]piperidin-4-ol Chemical compound C=1C=C(OC=2C=NC=CC=2)C(C)=CC=1NC(C1=C2)=NC=NC1=CC=C2C#CC1(O)CCNCC1 MYOQDKDWYZIYFU-UHFFFAOYSA-N 0.000 description 1
• CAYNELBWWGNADO-UHFFFAOYSA-N 4-[2-[4-[3-methyl-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-6-yl]ethynyl]-1,3-oxazolidin-2-one Chemical compound C1=NC(C)=CC=C1OC(C(=C1)C)=CC=C1NC1=NC=NC2=CC=C(C#CC3NC(=O)OC3)C=C12 CAYNELBWWGNADO-UHFFFAOYSA-N 0.000 description 1
• ZOTHZGBAKYILIX-UHFFFAOYSA-N 4-[4-(3-methyl-4-pyridin-3-yloxyanilino)quinazolin-6-yl]but-3-yn-1-ol Chemical compound CC1=CC(NC=2C3=CC(=CC=C3N=CN=2)C#CCCO)=CC=C1OC1=CC=CN=C1 ZOTHZGBAKYILIX-UHFFFAOYSA-N 0.000 description 1
• YVTDWTJRWMUTBA-UHFFFAOYSA-N 4-[4-(3-methyl-4-pyridin-3-yloxyanilino)quinazolin-6-yl]but-3-yne-1,2-diol Chemical compound CC1=CC(NC=2C3=CC(=CC=C3N=CN=2)C#CC(O)CO)=CC=C1OC1=CC=CN=C1 YVTDWTJRWMUTBA-UHFFFAOYSA-N 0.000 description 1
• QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
• CYZMUIMLRBJSRO-UHFFFAOYSA-N 4-[[4-(4-chlorophenoxy)phenyl]sulfonylamino]-n-hydroxyoxane-4-carboxamide Chemical compound C=1C=C(OC=2C=CC(Cl)=CC=2)C=CC=1S(=O)(=O)NC1(C(=O)NO)CCOCC1 CYZMUIMLRBJSRO-UHFFFAOYSA-N 0.000 description 1
• ZBRHTUMWSDPCMI-UHFFFAOYSA-N 4-[[4-(4-fluorophenoxy)phenyl]sulfonylamino]-n-hydroxyoxane-4-carboxamide Chemical compound C=1C=C(OC=2C=CC(F)=CC=2)C=CC=1S(=O)(=O)NC1(C(=O)NO)CCOCC1 ZBRHTUMWSDPCMI-UHFFFAOYSA-N 0.000 description 1
• YDDONLRYEJSTQK-UHFFFAOYSA-N 4-ethynylpiperidine-1-carboxylic acid Chemical compound OC(=O)N1CCC(C#C)CC1 YDDONLRYEJSTQK-UHFFFAOYSA-N 0.000 description 1
• MIKGLWJHHGPLAY-UHFFFAOYSA-N 4-methyl-N-[3-[4-[3-methyl-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-6-yl]prop-2-ynyl]piperazine-1-carboxamide Chemical compound CC=1C=C(C=CC=1OC=1C=NC(=CC=1)C)NC1=NC=NC2=CC=C(C=C12)C#CCNC(=O)N1CCN(CC1)C MIKGLWJHHGPLAY-UHFFFAOYSA-N 0.000 description 1
• FQDRGFMKVTZVAN-UHFFFAOYSA-N 5-[2-[4-[3-methyl-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-6-yl]ethynyl]morpholin-3-one Chemical compound C1=NC(C)=CC=C1OC(C(=C1)C)=CC=C1NC1=NC=NC2=CC=C(C#CC3NC(=O)COC3)C=C12 FQDRGFMKVTZVAN-UHFFFAOYSA-N 0.000 description 1
• XNKZVIFFFDKBNQ-UHFFFAOYSA-N 6-(3-aminobut-1-ynyl)-N-[3-methyl-4-(6-methylpyridin-3-yl)oxyphenyl]quinazolin-4-amine Chemical compound C12=CC(C#CC(N)C)=CC=C2N=CN=C1NC(C=C1C)=CC=C1OC1=CC=C(C)N=C1 XNKZVIFFFDKBNQ-UHFFFAOYSA-N 0.000 description 1
• YEZDLWFROAWJTP-UHFFFAOYSA-N 6-(3-aminoprop-1-ynyl)-N-(3-chloro-4-pyridin-3-yloxyphenyl)quinazolin-4-amine Chemical compound C12=CC(C#CCN)=CC=C2N=CN=C1NC(C=C1Cl)=CC=C1OC1=CC=CN=C1 YEZDLWFROAWJTP-UHFFFAOYSA-N 0.000 description 1
• AUJLDCMPGHEXFI-UHFFFAOYSA-N 6-(3-methoxyprop-1-ynyl)-n-(3-methyl-4-pyridin-3-yloxyphenyl)quinazolin-4-amine Chemical compound C12=CC(C#CCOC)=CC=C2N=CN=C1NC(C=C1C)=CC=C1OC1=CC=CN=C1 AUJLDCMPGHEXFI-UHFFFAOYSA-N 0.000 description 1
• NTDAMGZQMTWFEJ-UHFFFAOYSA-N 6-(4-aminobut-1-ynyl)-N-(3-chloro-4-pyridin-3-yloxyphenyl)quinazolin-4-amine Chemical compound C12=CC(C#CCCN)=CC=C2N=CN=C1NC(C=C1Cl)=CC=C1OC1=CC=CN=C1 NTDAMGZQMTWFEJ-UHFFFAOYSA-N 0.000 description 1
• ZVWFLYLKKDYYSW-UHFFFAOYSA-N 6-(4-aminobut-1-ynyl)-n-(3-methyl-4-pyridin-3-yloxyphenyl)quinazolin-4-amine Chemical compound CC1=CC(NC=2C3=CC(=CC=C3N=CN=2)C#CCCN)=CC=C1OC1=CC=CN=C1 ZVWFLYLKKDYYSW-UHFFFAOYSA-N 0.000 description 1
• VDGWKXZZVNGTKL-UHFFFAOYSA-N 6-(4-methoxybut-1-ynyl)-n-(3-methyl-4-pyridin-3-yloxyphenyl)quinazolin-4-amine Chemical compound C12=CC(C#CCCOC)=CC=C2N=CN=C1NC(C=C1C)=CC=C1OC1=CC=CN=C1 VDGWKXZZVNGTKL-UHFFFAOYSA-N 0.000 description 1
• ZUUUNTMRJZMESZ-UHFFFAOYSA-N 6-[2-(1-aminocyclobutyl)ethynyl]-n-[3-methyl-4-(6-methylpyridin-3-yl)oxyphenyl]quinazolin-4-amine Chemical compound C1=NC(C)=CC=C1OC(C(=C1)C)=CC=C1NC1=NC=NC2=CC=C(C#CC3(N)CCC3)C=C12 ZUUUNTMRJZMESZ-UHFFFAOYSA-N 0.000 description 1
• GPNPEVTWQDKDIM-UHFFFAOYSA-N 6-[2-(1-aminocyclopropyl)ethynyl]-n-[3-methyl-4-(6-methylpyridin-3-yl)oxyphenyl]quinazolin-4-amine Chemical compound C1=NC(C)=CC=C1OC(C(=C1)C)=CC=C1NC1=NC=NC2=CC=C(C#CC3(N)CC3)C=C12 GPNPEVTWQDKDIM-UHFFFAOYSA-N 0.000 description 1
• PUGXMZKDRVGIHC-UHFFFAOYSA-N 6-iodo-1h-quinazolin-4-one Chemical compound N1C=NC(=O)C2=CC(I)=CC=C21 PUGXMZKDRVGIHC-UHFFFAOYSA-N 0.000 description 1
• ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
• ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 1
• 241000220479 Acacia Species 0.000 description 1
• QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
• ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 1
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
• USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
• 239000005695 Ammonium acetate Substances 0.000 description 1
• 108090000644 Angiozyme Proteins 0.000 description 1
• 208000035143 Bacterial infection Diseases 0.000 description 1
• 206010065687 Bone loss Diseases 0.000 description 1
• 241000588832 Bordetella pertussis Species 0.000 description 1
• 241000589969 Borreliella burgdorferi Species 0.000 description 1
• 229910000906 Bronze Inorganic materials 0.000 description 1
• DXUTWLNDSOKRHS-UHFFFAOYSA-N C1=CC(=CN=C1)OC2=C(C=C(C=C2)NC3=NC=NC4=C3C=C(C=C4)C#CCNC(=O)S)Cl Chemical compound C1=CC(=CN=C1)OC2=C(C=C(C=C2)NC3=NC=NC4=C3C=C(C=C4)C#CCNC(=O)S)Cl DXUTWLNDSOKRHS-UHFFFAOYSA-N 0.000 description 1
• 108091007914 CDKs Proteins 0.000 description 1
• BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
• ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
• FQVBGLNGIDJJID-UHFFFAOYSA-N ClC1=NC=NC2=CC=C(C=C12)C#CC1CCN(CC1)C(=O)O Chemical compound ClC1=NC=NC2=CC=C(C=C12)C#CC1CCN(CC1)C(=O)O FQVBGLNGIDJJID-UHFFFAOYSA-N 0.000 description 1
• 102100027995 Collagenase 3 Human genes 0.000 description 1
• 108050005238 Collagenase 3 Proteins 0.000 description 1
• RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
• 201000000054 Coronary Restenosis Diseases 0.000 description 1
• 206010056489 Coronary artery restenosis Diseases 0.000 description 1
• VHHGUBHZBLPTKL-UHFFFAOYSA-N Cp-471358 Chemical compound C=1C=C(OC=2C=CC(F)=CC=2)C=CC=1S(=O)(=O)N(CCC(O)=O)C1(C(=O)NO)CCCC1 VHHGUBHZBLPTKL-UHFFFAOYSA-N 0.000 description 1
• 102000003903 Cyclin-dependent kinases Human genes 0.000 description 1
• 108090000266 Cyclin-dependent kinases Proteins 0.000 description 1
• 102000010907 Cyclooxygenase 2 Human genes 0.000 description 1
• 108010037462 Cyclooxygenase 2 Proteins 0.000 description 1
• CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
• UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
• DSLZVSRJTYRBFB-LLEIAEIESA-N D-glucaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O DSLZVSRJTYRBFB-LLEIAEIESA-N 0.000 description 1
• RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
• AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
• 101100481408 Danio rerio tie2 gene Proteins 0.000 description 1
• YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
• FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
• 206010012689 Diabetic retinopathy Diseases 0.000 description 1
• QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
• 102400001368 Epidermal growth factor Human genes 0.000 description 1
• 101800003838 Epidermal growth factor Proteins 0.000 description 1
• 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
• 201000001342 Fallopian tube cancer Diseases 0.000 description 1
• 208000013452 Fallopian tube neoplasm Diseases 0.000 description 1
• 208000009849 Female Genital Neoplasms Diseases 0.000 description 1
• PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
• GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
• BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
• VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
• 206010061968 Gastric neoplasm Diseases 0.000 description 1
• 201000003741 Gastrointestinal carcinoma Diseases 0.000 description 1
• 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
• 108010010803 Gelatin Proteins 0.000 description 1
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
• 108010024636 Glutathione Proteins 0.000 description 1
• 102000009465 Growth Factor Receptors Human genes 0.000 description 1
• 108010009202 Growth Factor Receptors Proteins 0.000 description 1
• 239000007821 HATU Substances 0.000 description 1
• 239000007995 HEPES buffer Substances 0.000 description 1
• 102100031547 HLA class II histocompatibility antigen, DO alpha chain Human genes 0.000 description 1
• 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
• 101000866278 Homo sapiens HLA class II histocompatibility antigen, DO alpha chain Proteins 0.000 description 1
• CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
• LCWXJXMHJVIJFK-UHFFFAOYSA-N Hydroxylysine Natural products NCC(O)CC(N)CC(O)=O LCWXJXMHJVIJFK-UHFFFAOYSA-N 0.000 description 1
• PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
• VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 1
• 206010020880 Hypertrophy Diseases 0.000 description 1
• 208000028482 Hypothalamic disease Diseases 0.000 description 1
• 208000025282 Hypothalamo-pituitary disease Diseases 0.000 description 1
• 102000014150 Interferons Human genes 0.000 description 1
• 108010050904 Interferons Proteins 0.000 description 1
• SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 description 1
• AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
• UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 description 1
• SNDPXSYFESPGGJ-UHFFFAOYSA-N L-norVal-OH Natural products CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 description 1
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
• JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
• 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
• 229940124761 MMP inhibitor Drugs 0.000 description 1
• 102100027998 Macrophage metalloelastase Human genes 0.000 description 1
• 101710187853 Macrophage metalloelastase Proteins 0.000 description 1
• 102100030417 Matrilysin Human genes 0.000 description 1
• 108090000855 Matrilysin Proteins 0.000 description 1
• 102000002274 Matrix Metalloproteinases Human genes 0.000 description 1
• 108010000684 Matrix Metalloproteinases Proteins 0.000 description 1
• 241000699666 Mus <mouse, genus> Species 0.000 description 1
• 101100481410 Mus musculus Tek gene Proteins 0.000 description 1
• JDHILDINMRGULE-LURJTMIESA-N N(pros)-methyl-L-histidine Chemical compound CN1C=NC=C1C[C@H](N)C(O)=O JDHILDINMRGULE-LURJTMIESA-N 0.000 description 1
• JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 1
• FFDGPVCHZBVARC-UHFFFAOYSA-N N,N-dimethylglycine Chemical class CN(C)CC(O)=O FFDGPVCHZBVARC-UHFFFAOYSA-N 0.000 description 1
• JRUYAXYNIJRDMR-UHFFFAOYSA-N N-[2-methyl-4-[4-[3-methyl-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-6-yl]but-3-yn-2-yl]morpholine-4-carboxamide Chemical compound CC(C#CC=1C=C2C(=NC=NC2=CC=1)NC1=CC(=C(C=C1)OC=1C=NC(=CC=1)C)C)(C)NC(=O)N1CCOCC1 JRUYAXYNIJRDMR-UHFFFAOYSA-N 0.000 description 1
• OKXNDMYBZFXHSU-UHFFFAOYSA-N N-[2-methyl-4-[4-[3-methyl-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-6-yl]but-3-yn-2-yl]piperazine-1-carboxamide Chemical compound CC(C#CC=1C=C2C(=NC=NC2=CC=1)NC1=CC(=C(C=C1)OC=1C=NC(=CC=1)C)C)(C)NC(=O)N1CCNCC1 OKXNDMYBZFXHSU-UHFFFAOYSA-N 0.000 description 1
• SZTOGAZHPVYODG-UHFFFAOYSA-N N-[3-[4-(3-chloro-4-pyridin-3-yloxyanilino)quinazolin-6-yl]prop-2-ynyl]oxolane-3-carboxamide Chemical compound ClC=1C=C(C=CC=1OC=1C=NC=CC=1)NC1=NC=NC2=CC=C(C=C12)C#CCNC(=O)C1COCC1 SZTOGAZHPVYODG-UHFFFAOYSA-N 0.000 description 1
• XUJQNBFIGSCWQN-UHFFFAOYSA-N N-[3-[4-(3-methyl-4-pyridin-3-yloxyanilino)quinazolin-6-yl]prop-2-ynyl]azetidine-2-carboxamide Chemical compound CC=1C=C(C=CC=1OC=1C=NC=CC=1)NC1=NC=NC2=CC=C(C=C12)C#CCNC(=O)C1NCC1 XUJQNBFIGSCWQN-UHFFFAOYSA-N 0.000 description 1
• YBVVQTXBFBZFMW-UHFFFAOYSA-N N-[3-[4-(3-methyl-4-pyridin-3-yloxyanilino)quinazolin-6-yl]prop-2-ynyl]cyclopropanecarboxamide Chemical compound CC=1C=C(C=CC=1OC=1C=NC=CC=1)NC1=NC=NC2=CC=C(C=C12)C#CCNC(=O)C1CC1 YBVVQTXBFBZFMW-UHFFFAOYSA-N 0.000 description 1
• PRNIJQITGDFYSL-UHFFFAOYSA-N N-[3-[4-(3-methyl-4-pyridin-3-yloxyanilino)quinazolin-6-yl]prop-2-ynyl]oxolane-2-carboxamide Chemical compound CC=1C=C(C=CC=1OC=1C=NC=CC=1)NC1=NC=NC2=CC=C(C=C12)C#CCNC(=O)C1OCCC1 PRNIJQITGDFYSL-UHFFFAOYSA-N 0.000 description 1
• ALRYOXWQWJFVLS-UHFFFAOYSA-N N-[3-[4-(3-methyl-4-pyridin-3-yloxyanilino)quinazolin-6-yl]prop-2-ynyl]oxolane-3-carboxamide Chemical compound CC=1C=C(C=CC=1OC=1C=NC=CC=1)NC1=NC=NC2=CC=C(C=C12)C#CCNC(=O)C1COCC1 ALRYOXWQWJFVLS-UHFFFAOYSA-N 0.000 description 1
• MONGNJIMUSSUET-UHFFFAOYSA-N N-[3-[4-[3-chloro-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-6-yl]prop-2-ynyl]-2-(methoxymethyl)pyrrolidine-1-carboxamide Chemical compound ClC=1C=C(C=CC=1OC=1C=NC(=CC=1)C)NC1=NC=NC2=CC=C(C=C12)C#CCNC(=O)N1C(CCC1)COC MONGNJIMUSSUET-UHFFFAOYSA-N 0.000 description 1
• DQLSKBNNKZYUTC-UHFFFAOYSA-N N-[3-[4-[3-chloro-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-6-yl]prop-2-ynyl]azetidine-1-carboxamide Chemical compound ClC=1C=C(C=CC=1OC=1C=NC(=CC=1)C)NC1=NC=NC2=CC=C(C=C12)C#CCNC(=O)N1CCC1 DQLSKBNNKZYUTC-UHFFFAOYSA-N 0.000 description 1
• DJTRBMWTQISCAU-UHFFFAOYSA-N N-[3-[4-[3-chloro-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-6-yl]prop-2-ynyl]cyclobutanecarboxamide Chemical compound ClC=1C=C(C=CC=1OC=1C=NC(=CC=1)C)NC1=NC=NC2=CC=C(C=C12)C#CCNC(=O)C1CCC1 DJTRBMWTQISCAU-UHFFFAOYSA-N 0.000 description 1
• HUBVUSBYFSYMDF-UHFFFAOYSA-N N-[3-[4-[3-chloro-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-6-yl]prop-2-ynyl]morpholine-4-carboxamide Chemical compound ClC=1C=C(C=CC=1OC=1C=NC(=CC=1)C)NC1=NC=NC2=CC=C(C=C12)C#CCNC(=O)N1CCOCC1 HUBVUSBYFSYMDF-UHFFFAOYSA-N 0.000 description 1
• NUYNXTIBERHUMM-UHFFFAOYSA-N N-[3-[4-[3-chloro-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-6-yl]prop-2-ynyl]piperazine-1-carboxamide Chemical compound ClC=1C=C(C=CC=1OC=1C=NC(=CC=1)C)NC1=NC=NC2=CC=C(C=C12)C#CCNC(=O)N1CCNCC1 NUYNXTIBERHUMM-UHFFFAOYSA-N 0.000 description 1
• PHOBHTRTNDYIIU-UHFFFAOYSA-N N-[3-[4-[3-chloro-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-6-yl]prop-2-ynyl]pyrrolidine-1-carboxamide Chemical compound ClC=1C=C(C=CC=1OC=1C=NC(=CC=1)C)NC1=NC=NC2=CC=C(C=C12)C#CCNC(=O)N1CCCC1 PHOBHTRTNDYIIU-UHFFFAOYSA-N 0.000 description 1
• SHTGGHOYIPYHND-UHFFFAOYSA-N N-[3-[4-[3-methyl-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-6-yl]prop-2-ynyl]azetidine-1-carboxamide Chemical compound CC=1C=C(C=CC=1OC=1C=NC(=CC=1)C)NC1=NC=NC2=CC=C(C=C12)C#CCNC(=O)N1CCC1 SHTGGHOYIPYHND-UHFFFAOYSA-N 0.000 description 1
• UUJHBRLGVGQLHT-UHFFFAOYSA-N N-[3-[4-[3-methyl-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-6-yl]prop-2-ynyl]cyclopropanecarboxamide Chemical compound CC=1C=C(C=CC=1OC=1C=NC(=CC=1)C)NC1=NC=NC2=CC=C(C=C12)C#CCNC(=O)C1CC1 UUJHBRLGVGQLHT-UHFFFAOYSA-N 0.000 description 1
• KOGABOXFEKSQPX-UHFFFAOYSA-N N-[3-[4-[3-methyl-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-6-yl]prop-2-ynyl]morpholine-4-carboxamide Chemical compound CC=1C=C(C=CC=1OC=1C=NC(=CC=1)C)NC1=NC=NC2=CC=C(C=C12)C#CCNC(=O)N1CCOCC1 KOGABOXFEKSQPX-UHFFFAOYSA-N 0.000 description 1
• XGVOJXCEVXXIDG-UHFFFAOYSA-N N-[3-[4-[3-methyl-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-6-yl]prop-2-ynyl]oxolane-3-carboxamide Chemical compound CC=1C=C(C=CC=1OC=1C=NC(=CC=1)C)NC1=NC=NC2=CC=C(C=C12)C#CCNC(=O)C1COCC1 XGVOJXCEVXXIDG-UHFFFAOYSA-N 0.000 description 1
• OHNHAELCGKHMEF-UHFFFAOYSA-N N-[3-[4-[3-methyl-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-6-yl]prop-2-ynyl]piperidine-1-carboxamide Chemical compound CC=1C=C(C=CC=1OC=1C=NC(=CC=1)C)NC1=NC=NC2=CC=C(C=C12)C#CCNC(=O)N1CCCCC1 OHNHAELCGKHMEF-UHFFFAOYSA-N 0.000 description 1
• NXNNSBUWVDAQCC-UHFFFAOYSA-N N-[4-[4-(3-methyl-4-pyridin-3-yloxyanilino)quinazolin-6-yl]but-3-ynyl]cyclopropanecarboxamide Chemical compound CC=1C=C(C=CC=1OC=1C=NC=CC=1)NC1=NC=NC2=CC=C(C=C12)C#CCCNC(=O)C1CC1 NXNNSBUWVDAQCC-UHFFFAOYSA-N 0.000 description 1
• VDTQYGIUTAWNGL-UHFFFAOYSA-N N-[4-[4-[3-methyl-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-6-yl]but-3-yn-2-yl]morpholine-4-carboxamide Chemical compound CC(C#CC=1C=C2C(=NC=NC2=CC=1)NC1=CC(=C(C=C1)OC=1C=NC(=CC=1)C)C)NC(=O)N1CCOCC1 VDTQYGIUTAWNGL-UHFFFAOYSA-N 0.000 description 1
• LKJPYSCBVHEWIU-UHFFFAOYSA-N N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide Chemical compound C=1C=C(C#N)C(C(F)(F)F)=CC=1NC(=O)C(O)(C)CS(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-UHFFFAOYSA-N 0.000 description 1
• FTFRZXFNZVCRSK-UHFFFAOYSA-N N4-(3-chloro-4-fluorophenyl)-N6-(1-methyl-4-piperidinyl)pyrimido[5,4-d]pyrimidine-4,6-diamine Chemical compound C1CN(C)CCC1NC1=NC=C(N=CN=C2NC=3C=C(Cl)C(F)=CC=3)C2=N1 FTFRZXFNZVCRSK-UHFFFAOYSA-N 0.000 description 1
• 229910002651 NO3 Inorganic materials 0.000 description 1
• 102100030411 Neutrophil collagenase Human genes 0.000 description 1
• 101710118230 Neutrophil collagenase Proteins 0.000 description 1
• NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
• 208000022873 Ocular disease Diseases 0.000 description 1
• 102000043276 Oncogene Human genes 0.000 description 1
• AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
• UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
• 241000150452 Orthohantavirus Species 0.000 description 1
• 208000010191 Osteitis Deformans Diseases 0.000 description 1
• 208000001132 Osteoporosis Diseases 0.000 description 1
• 102000016979 Other receptors Human genes 0.000 description 1
• 208000027868 Paget disease Diseases 0.000 description 1
• 102000003992 Peroxidases Human genes 0.000 description 1
• OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
• ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
• 206010063664 Presumed ocular histoplasmosis syndrome Diseases 0.000 description 1
• 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 1
• 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 1
• 208000007135 Retinal Neovascularization Diseases 0.000 description 1
• 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
• DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
• 229920002472 Starch Polymers 0.000 description 1
• 241001505901 Streptococcus sp. 'group A' Species 0.000 description 1
• 102100030416 Stromelysin-1 Human genes 0.000 description 1
• 101710108790 Stromelysin-1 Proteins 0.000 description 1
• 102100028848 Stromelysin-2 Human genes 0.000 description 1
• 101710108792 Stromelysin-2 Proteins 0.000 description 1
• 102100028847 Stromelysin-3 Human genes 0.000 description 1
• 108050005271 Stromelysin-3 Proteins 0.000 description 1
• 229930006000 Sucrose Natural products 0.000 description 1
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
• QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
• 108091008605 VEGF receptors Proteins 0.000 description 1
• 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 1
• JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
• 206010047741 Vulval cancer Diseases 0.000 description 1
• 241000607734 Yersinia <bacteria> Species 0.000 description 1
• 230000009471 action Effects 0.000 description 1
• 125000002252 acyl group Chemical group 0.000 description 1
• TTWYZDPBDWHJOR-IDIVVRGQSA-L adenosine triphosphate disodium Chemical compound [Na+].[Na+].C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O TTWYZDPBDWHJOR-IDIVVRGQSA-L 0.000 description 1
• 239000002671 adjuvant Substances 0.000 description 1
• 229940009456 adriamycin Drugs 0.000 description 1
• 238000012382 advanced drug delivery Methods 0.000 description 1
• 206010064930 age-related macular degeneration Diseases 0.000 description 1
• 239000000783 alginic acid Substances 0.000 description 1
• 235000010443 alginic acid Nutrition 0.000 description 1
• 229920000615 alginic acid Polymers 0.000 description 1
• 229960001126 alginic acid Drugs 0.000 description 1
• 150000004781 alginic acids Chemical class 0.000 description 1
• 125000002009 alkene group Chemical group 0.000 description 1
• 150000004703 alkoxides Chemical class 0.000 description 1
• 125000002947 alkylene group Chemical group 0.000 description 1
• 125000003368 amide group Chemical group 0.000 description 1
• 229940043376 ammonium acetate Drugs 0.000 description 1
• 235000019257 ammonium acetate Nutrition 0.000 description 1
• 230000033115 angiogenesis Effects 0.000 description 1
• 230000002491 angiogenic effect Effects 0.000 description 1
• 150000001450 anions Chemical class 0.000 description 1
• 229940046836 anti-estrogen Drugs 0.000 description 1
• 230000001833 anti-estrogenic effect Effects 0.000 description 1
• 230000000259 anti-tumor effect Effects 0.000 description 1
• 230000005975 antitumor immune response Effects 0.000 description 1
• 239000003125 aqueous solvent Substances 0.000 description 1
• 239000007900 aqueous suspension Substances 0.000 description 1
• 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
• 150000001502 aryl halides Chemical class 0.000 description 1
• 229940072107 ascorbate Drugs 0.000 description 1
• 235000010323 ascorbic acid Nutrition 0.000 description 1
• 239000011668 ascorbic acid Substances 0.000 description 1
• 238000003556 assay Methods 0.000 description 1
• 210000001130 astrocyte Anatomy 0.000 description 1
• 238000011717 athymic nude mouse Methods 0.000 description 1
• 230000002238 attenuated effect Effects 0.000 description 1
• VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
• HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 1
• 208000022362 bacterial infectious disease Diseases 0.000 description 1
• 239000011324 bead Substances 0.000 description 1
• 230000008901 benefit Effects 0.000 description 1
• SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
• 229940077388 benzenesulfonate Drugs 0.000 description 1
• 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
• 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
• WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
• 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
• 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
• 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
• 229940000635 beta-alanine Drugs 0.000 description 1
• 210000004952 blastocoel Anatomy 0.000 description 1
• 230000037396 body weight Effects 0.000 description 1
• 210000000988 bone and bone Anatomy 0.000 description 1
• KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
• 239000004327 boric acid Substances 0.000 description 1
• 210000004556 brain Anatomy 0.000 description 1
• 210000000481 breast Anatomy 0.000 description 1
• GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
• 229910052794 bromium Inorganic materials 0.000 description 1
• 239000010974 bronze Substances 0.000 description 1
• 239000007853 buffer solution Substances 0.000 description 1
• DNSISZSEWVHGLH-UHFFFAOYSA-N butanamide Chemical compound CCCC(N)=O DNSISZSEWVHGLH-UHFFFAOYSA-N 0.000 description 1
• 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 239000002775 capsule Substances 0.000 description 1
• 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
• 125000005587 carbonate group Chemical group 0.000 description 1
• 229960004562 carboplatin Drugs 0.000 description 1
• 125000002843 carboxylic acid group Chemical group 0.000 description 1
• 231100000357 carcinogen Toxicity 0.000 description 1
• 231100000315 carcinogenic Toxicity 0.000 description 1
• 239000003183 carcinogenic agent Substances 0.000 description 1
• 239000000969 carrier Substances 0.000 description 1
• 229940097647 casodex Drugs 0.000 description 1
• 239000003054 catalyst Substances 0.000 description 1
• 210000000170 cell membrane Anatomy 0.000 description 1
• 230000010307 cell transformation Effects 0.000 description 1
• 239000013043 chemical agent Substances 0.000 description 1
• 238000002512 chemotherapy Methods 0.000 description 1
• 239000012320 chlorinating reagent Substances 0.000 description 1
• 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
• 229940001468 citrate Drugs 0.000 description 1
• 238000011278 co-treatment Methods 0.000 description 1
• 230000030944 contact inhibition Effects 0.000 description 1
• 239000012059 conventional drug carrier Substances 0.000 description 1
• 238000007796 conventional method Methods 0.000 description 1
• 238000001816 cooling Methods 0.000 description 1
• 229910052802 copper Inorganic materials 0.000 description 1
• 239000010949 copper Substances 0.000 description 1
• KUNSUQLRTQLHQQ-UHFFFAOYSA-N copper tin Chemical compound [Cu].[Sn] KUNSUQLRTQLHQQ-UHFFFAOYSA-N 0.000 description 1
• 239000006071 cream Substances 0.000 description 1
• 108010044165 crotoxin drug combination cardiotoxin Proteins 0.000 description 1
• 239000012043 crude product Substances 0.000 description 1
• 210000000448 cultured tumor cell Anatomy 0.000 description 1
• TXWOGHSRPAYOML-UHFFFAOYSA-N cyclobutanecarboxylic acid Chemical compound OC(=O)C1CCC1 TXWOGHSRPAYOML-UHFFFAOYSA-N 0.000 description 1
• 229960004397 cyclophosphamide Drugs 0.000 description 1
• 229940127089 cytotoxic agent Drugs 0.000 description 1
• YSMODUONRAFBET-UHFFFAOYSA-N delta-DL-hydroxylysine Natural products NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 description 1
• 229910052805 deuterium Inorganic materials 0.000 description 1
• 239000008121 dextrose Substances 0.000 description 1
• 125000002576 diazepinyl group Chemical group N1N=C(C=CC=C1)* 0.000 description 1
• 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 description 1
• 125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 description 1
• 125000005057 dihydrothienyl group Chemical group S1C(CC=C1)* 0.000 description 1
• 239000003085 diluting agent Substances 0.000 description 1
• 125000000532 dioxanyl group Chemical group 0.000 description 1
• 125000005883 dithianyl group Chemical group 0.000 description 1
• 125000005411 dithiolanyl group Chemical group S1SC(CC1)* 0.000 description 1
• PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
• 239000003814 drug Substances 0.000 description 1
• 238000001035 drying Methods 0.000 description 1
• 239000003995 emulsifying agent Substances 0.000 description 1
• 239000000839 emulsion Substances 0.000 description 1
• 230000002708 enhancing effect Effects 0.000 description 1
• 229940116977 epidermal growth factor Drugs 0.000 description 1
• SIHZWGODIRRSRA-ONEGZZNKSA-N erbstatin Chemical compound OC1=CC=C(O)C(\C=C\NC=O)=C1 SIHZWGODIRRSRA-ONEGZZNKSA-N 0.000 description 1
• YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 description 1
• 201000004101 esophageal cancer Diseases 0.000 description 1
• 210000003238 esophagus Anatomy 0.000 description 1
• 239000000328 estrogen antagonist Substances 0.000 description 1
• CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
• CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical compound CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 1
• RWMJRMPOKXSHHI-UHFFFAOYSA-N ethenylboron Chemical group [B]C=C RWMJRMPOKXSHHI-UHFFFAOYSA-N 0.000 description 1
• BADWIIDKTXQYLW-UHFFFAOYSA-N ethenylstannane Chemical group [SnH3]C=C BADWIIDKTXQYLW-UHFFFAOYSA-N 0.000 description 1
• OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 1
• 230000001747 exhibiting effect Effects 0.000 description 1
• 125000004030 farnesyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• 239000000945 filler Substances 0.000 description 1
• 239000000706 filtrate Substances 0.000 description 1
• 238000001914 filtration Methods 0.000 description 1
• 239000012467 final product Substances 0.000 description 1
• 239000011737 fluorine Substances 0.000 description 1
• 229960002949 fluorouracil Drugs 0.000 description 1
• 235000003599 food sweetener Nutrition 0.000 description 1
• 238000009472 formulation Methods 0.000 description 1
• 238000001640 fractional crystallisation Methods 0.000 description 1
• 229940050411 fumarate Drugs 0.000 description 1
• 125000000524 functional group Chemical group 0.000 description 1
• 125000004612 furopyridinyl group Chemical group O1C(=CC2=C1C=CC=N2)* 0.000 description 1
• 125000002541 furyl group Chemical group 0.000 description 1
• 230000004927 fusion Effects 0.000 description 1
• 108020001507 fusion proteins Proteins 0.000 description 1
• 102000037865 fusion proteins Human genes 0.000 description 1
• 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
• XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 1
• 239000008273 gelatin Substances 0.000 description 1
• 229920000159 gelatin Polymers 0.000 description 1
• 239000007903 gelatin capsule Substances 0.000 description 1
• 235000019322 gelatine Nutrition 0.000 description 1
• 235000011852 gelatine desserts Nutrition 0.000 description 1
• 230000000762 glandular Effects 0.000 description 1
• 230000002518 glial effect Effects 0.000 description 1
• 208000005017 glioblastoma Diseases 0.000 description 1
• 201000003617 glucocorticoid-induced osteoporosis Diseases 0.000 description 1
• 229940050410 gluconate Drugs 0.000 description 1
• 229940097042 glucuronate Drugs 0.000 description 1
• 229930195712 glutamate Natural products 0.000 description 1
• 239000004220 glutamic acid Substances 0.000 description 1
• 229960003180 glutathione Drugs 0.000 description 1
• 235000011187 glycerol Nutrition 0.000 description 1
• 230000002440 hepatic effect Effects 0.000 description 1
• 229940022353 herceptin Drugs 0.000 description 1
• 125000001072 heteroaryl group Chemical group 0.000 description 1
• XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
• 238000005984 hydrogenation reaction Methods 0.000 description 1
• QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
• 230000003301 hydrolyzing effect Effects 0.000 description 1
• QJHBJHUKURJDLG-UHFFFAOYSA-N hydroxy-L-lysine Natural products NCCCCC(NO)C(O)=O QJHBJHUKURJDLG-UHFFFAOYSA-N 0.000 description 1
• 229960001330 hydroxycarbamide Drugs 0.000 description 1
• 229960002591 hydroxyproline Drugs 0.000 description 1
• 230000002390 hyperplastic effect Effects 0.000 description 1
• 230000003463 hyperproliferative effect Effects 0.000 description 1
• 125000002636 imidazolinyl group Chemical group 0.000 description 1
• 125000002883 imidazolyl group Chemical group 0.000 description 1
• 208000026278 immune system disease Diseases 0.000 description 1
• 238000002513 implantation Methods 0.000 description 1
• 238000000338 in vitro Methods 0.000 description 1
• 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
• 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
• 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
• 125000001041 indolyl group Chemical group 0.000 description 1
• 230000006698 induction Effects 0.000 description 1
• 239000003701 inert diluent Substances 0.000 description 1
• 230000002757 inflammatory effect Effects 0.000 description 1
• 238000001802 infusion Methods 0.000 description 1
• 239000004615 ingredient Substances 0.000 description 1
• 230000003993 interaction Effects 0.000 description 1
• 239000012444 intercalating antibiotic Substances 0.000 description 1
• 229940079322 interferon Drugs 0.000 description 1
• 210000000936 intestine Anatomy 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• 238000007912 intraperitoneal administration Methods 0.000 description 1
• 238000001990 intravenous administration Methods 0.000 description 1
• PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
• 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
• 238000002955 isolation Methods 0.000 description 1
• TWBYWOBDOCUKOW-UHFFFAOYSA-M isonicotinate Chemical compound [O-]C(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-M 0.000 description 1
• 125000001786 isothiazolyl group Chemical group 0.000 description 1
• 125000000842 isoxazolyl group Chemical group 0.000 description 1
• 238000000021 kinase assay Methods 0.000 description 1
• 239000008101 lactose Substances 0.000 description 1
• 239000003446 ligand Substances 0.000 description 1
• 229910052744 lithium Inorganic materials 0.000 description 1
• 210000004185 liver Anatomy 0.000 description 1
• 239000000314 lubricant Substances 0.000 description 1
• 210000002540 macrophage Anatomy 0.000 description 1
• 208000002780 macular degeneration Diseases 0.000 description 1
• 229910001629 magnesium chloride Inorganic materials 0.000 description 1
• 235000019359 magnesium stearate Nutrition 0.000 description 1
• VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
• 230000036210 malignancy Effects 0.000 description 1
• 208000027202 mammary Paget disease Diseases 0.000 description 1
• 229940121386 matrix metalloproteinase inhibitor Drugs 0.000 description 1
• 239000003771 matrix metalloproteinase inhibitor Substances 0.000 description 1
• 238000000691 measurement method Methods 0.000 description 1
• 239000002609 medium Substances 0.000 description 1
• 230000002503 metabolic effect Effects 0.000 description 1
• 206010061289 metastatic neoplasm Diseases 0.000 description 1
• 150000005217 methyl ethers Chemical class 0.000 description 1
• PBAROTCYIIEPJX-UHFFFAOYSA-N methyl n-[3-[4-(3-methyl-4-pyridin-3-yloxyanilino)quinazolin-6-yl]prop-2-ynyl]carbamate Chemical compound C12=CC(C#CCNC(=O)OC)=CC=C2N=CN=C1NC(C=C1C)=CC=C1OC1=CC=CN=C1 PBAROTCYIIEPJX-UHFFFAOYSA-N 0.000 description 1
• TWQMDTXSAXCWDX-UHFFFAOYSA-N methyl n-[3-[4-[3-chloro-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-6-yl]prop-2-ynyl]carbamate Chemical compound C12=CC(C#CCNC(=O)OC)=CC=C2N=CN=C1NC(C=C1Cl)=CC=C1OC1=CC=C(C)N=C1 TWQMDTXSAXCWDX-UHFFFAOYSA-N 0.000 description 1
• 230000000813 microbial effect Effects 0.000 description 1
• 244000000010 microbial pathogen Species 0.000 description 1
• 238000002156 mixing Methods 0.000 description 1
• NJFHSZGMRDWPQP-UHFFFAOYSA-N n-(3-chloro-4-pyridin-3-yloxyphenyl)-6-(2-piperidin-4-ylethynyl)quinazolin-4-amine Chemical compound C=1C=C(OC=2C=NC=CC=2)C(Cl)=CC=1NC(C1=C2)=NC=NC1=CC=C2C#CC1CCNCC1 NJFHSZGMRDWPQP-UHFFFAOYSA-N 0.000 description 1
• AIKJFZUTYSMFBF-UHFFFAOYSA-N n-(3-chloro-4-pyridin-3-yloxyphenyl)-6-(4-methoxybut-1-ynyl)quinazolin-4-amine Chemical compound C12=CC(C#CCCOC)=CC=C2N=CN=C1NC(C=C1Cl)=CC=C1OC1=CC=CN=C1 AIKJFZUTYSMFBF-UHFFFAOYSA-N 0.000 description 1
• PEFSFJZZNCBILT-UHFFFAOYSA-N n-(3-fluoro-4-pyridin-3-yloxyphenyl)-6-(2-piperidin-4-ylethynyl)quinazolin-4-amine Chemical compound C=1C=C(OC=2C=NC=CC=2)C(F)=CC=1NC(C1=C2)=NC=NC1=CC=C2C#CC1CCNCC1 PEFSFJZZNCBILT-UHFFFAOYSA-N 0.000 description 1
• XEUDSXUDPRDHOV-UHFFFAOYSA-N n-(3-methyl-4-pyridin-3-yloxyphenyl)-6-(3-morpholin-4-ylprop-1-enyl)quinazolin-4-amine Chemical compound C=1C=C(OC=2C=NC=CC=2)C(C)=CC=1NC(C1=C2)=NC=NC1=CC=C2C=CCN1CCOCC1 XEUDSXUDPRDHOV-UHFFFAOYSA-N 0.000 description 1
• XEUDSXUDPRDHOV-ONEGZZNKSA-N n-(3-methyl-4-pyridin-3-yloxyphenyl)-6-[(e)-3-morpholin-4-ylprop-1-enyl]quinazolin-4-amine Chemical compound C=1C=C(OC=2C=NC=CC=2)C(C)=CC=1NC(C1=C2)=NC=NC1=CC=C2\C=C\CN1CCOCC1 XEUDSXUDPRDHOV-ONEGZZNKSA-N 0.000 description 1
• BXLGHZISKROJKN-MDZDMXLPSA-N n-[1-[(e)-2-[4-[3-chloro-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-6-yl]ethenyl]cyclopropyl]methanesulfonamide Chemical compound C1=NC(C)=CC=C1OC(C(=C1)Cl)=CC=C1NC(C1=C2)=NC=NC1=CC=C2\C=C\C1(NS(C)(=O)=O)CC1 BXLGHZISKROJKN-MDZDMXLPSA-N 0.000 description 1
• MXPBBGQWEAPVAD-UHFFFAOYSA-N n-[1-[2-[4-[3-chloro-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-6-yl]ethyl]cyclopropyl]methanesulfonamide Chemical compound C1=NC(C)=CC=C1OC(C(=C1)Cl)=CC=C1NC(C1=C2)=NC=NC1=CC=C2CCC1(NS(C)(=O)=O)CC1 MXPBBGQWEAPVAD-UHFFFAOYSA-N 0.000 description 1
• NRWWPPDNJGDRPV-UHFFFAOYSA-N n-[1-[2-[4-[3-methyl-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-6-yl]ethynyl]cyclobutyl]acetamide Chemical compound C=1C=C2N=CN=C(NC=3C=C(C)C(OC=4C=NC(C)=CC=4)=CC=3)C2=CC=1C#CC1(NC(=O)C)CCC1 NRWWPPDNJGDRPV-UHFFFAOYSA-N 0.000 description 1
• CYAQJZGPYLBVTO-UHFFFAOYSA-N n-[1-[2-[4-[3-methyl-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-6-yl]ethynyl]cyclopropyl]acetamide Chemical compound C=1C=C2N=CN=C(NC=3C=C(C)C(OC=4C=NC(C)=CC=4)=CC=3)C2=CC=1C#CC1(NC(=O)C)CC1 CYAQJZGPYLBVTO-UHFFFAOYSA-N 0.000 description 1
• FHFLDSLPIUMFKP-UHFFFAOYSA-N n-[1-hydroxy-4-[4-(3-methyl-4-pyridin-3-yloxyanilino)quinazolin-6-yl]but-3-yn-2-yl]acetamide Chemical compound C12=CC(C#CC(CO)NC(=O)C)=CC=C2N=CN=C1NC(C=C1C)=CC=C1OC1=CC=CN=C1 FHFLDSLPIUMFKP-UHFFFAOYSA-N 0.000 description 1
• VNRNBQKWKROHHR-UHFFFAOYSA-N n-[1-hydroxy-4-[4-[3-methyl-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-6-yl]but-3-yn-2-yl]acetamide Chemical compound C12=CC(C#CC(CO)NC(=O)C)=CC=C2N=CN=C1NC(C=C1C)=CC=C1OC1=CC=C(C)N=C1 VNRNBQKWKROHHR-UHFFFAOYSA-N 0.000 description 1
• GSKGSEURFDKYCS-UHFFFAOYSA-N n-[3-[4-(3-chloro-4-pyridin-3-yloxyanilino)quinazolin-6-yl]prop-2-ynyl]-2-(2-hydroxyethylsulfanyl)acetamide Chemical compound C12=CC(C#CCNC(=O)CSCCO)=CC=C2N=CN=C1NC(C=C1Cl)=CC=C1OC1=CC=CN=C1 GSKGSEURFDKYCS-UHFFFAOYSA-N 0.000 description 1
• VWBQZFJGGXKNHE-UHFFFAOYSA-N n-[3-[4-(3-chloro-4-pyridin-3-yloxyanilino)quinazolin-6-yl]prop-2-ynyl]-2-(dimethylamino)acetamide Chemical compound C12=CC(C#CCNC(=O)CN(C)C)=CC=C2N=CN=C1NC(C=C1Cl)=CC=C1OC1=CC=CN=C1 VWBQZFJGGXKNHE-UHFFFAOYSA-N 0.000 description 1
• JBULFWQJQATKAI-UHFFFAOYSA-N n-[3-[4-(3-chloro-4-pyridin-3-yloxyanilino)quinazolin-6-yl]prop-2-ynyl]-2-(methylamino)acetamide Chemical compound C12=CC(C#CCNC(=O)CNC)=CC=C2N=CN=C1NC(C=C1Cl)=CC=C1OC1=CC=CN=C1 JBULFWQJQATKAI-UHFFFAOYSA-N 0.000 description 1
• SCPUBJILQPOURF-UHFFFAOYSA-N n-[3-[4-(3-chloro-4-pyridin-3-yloxyanilino)quinazolin-6-yl]prop-2-ynyl]-2-fluoroacetamide Chemical compound C12=CC(C#CCNC(=O)CF)=CC=C2N=CN=C1NC(C=C1Cl)=CC=C1OC1=CC=CN=C1 SCPUBJILQPOURF-UHFFFAOYSA-N 0.000 description 1
• BLIHCUBTGPWVGQ-UHFFFAOYSA-N n-[3-[4-(3-chloro-4-pyridin-3-yloxyanilino)quinazolin-6-yl]prop-2-ynyl]-2-methoxyacetamide Chemical compound C12=CC(C#CCNC(=O)COC)=CC=C2N=CN=C1NC(C=C1Cl)=CC=C1OC1=CC=CN=C1 BLIHCUBTGPWVGQ-UHFFFAOYSA-N 0.000 description 1
• ZREJJHHKBCOZTJ-UHFFFAOYSA-N n-[3-[4-(3-chloro-4-pyridin-3-yloxyanilino)quinazolin-6-yl]prop-2-ynyl]-2-methylsulfonylacetamide Chemical compound C12=CC(C#CCNC(=O)CS(=O)(=O)C)=CC=C2N=CN=C1NC(C=C1Cl)=CC=C1OC1=CC=CN=C1 ZREJJHHKBCOZTJ-UHFFFAOYSA-N 0.000 description 1
• QDGQDNGUMOBLAT-UHFFFAOYSA-N n-[3-[4-(3-chloro-4-pyridin-3-yloxyanilino)quinazolin-6-yl]prop-2-ynyl]-2-oxopropanamide Chemical compound C12=CC(C#CCNC(=O)C(=O)C)=CC=C2N=CN=C1NC(C=C1Cl)=CC=C1OC1=CC=CN=C1 QDGQDNGUMOBLAT-UHFFFAOYSA-N 0.000 description 1
• MICUAJVSLVFPKZ-UHFFFAOYSA-N n-[3-[4-(3-ethynyl-4-pyridin-3-yloxyanilino)quinazolin-6-yl]prop-2-ynyl]-2-methoxyacetamide Chemical compound C12=CC(C#CCNC(=O)COC)=CC=C2N=CN=C1NC(C=C1C#C)=CC=C1OC1=CC=CN=C1 MICUAJVSLVFPKZ-UHFFFAOYSA-N 0.000 description 1
• BIBOSBCEJBGHPP-UHFFFAOYSA-N n-[3-[4-(3-ethynyl-4-pyridin-3-yloxyanilino)quinazolin-6-yl]prop-2-ynyl]acetamide Chemical compound C12=CC(C#CCNC(=O)C)=CC=C2N=CN=C1NC(C=C1C#C)=CC=C1OC1=CC=CN=C1 BIBOSBCEJBGHPP-UHFFFAOYSA-N 0.000 description 1
• KBXZFDDFWBCTEY-UHFFFAOYSA-N n-[3-[4-(3-fluoro-4-pyridin-3-yloxyanilino)quinazolin-6-yl]prop-2-ynyl]-2-methoxyacetamide Chemical compound C12=CC(C#CCNC(=O)COC)=CC=C2N=CN=C1NC(C=C1F)=CC=C1OC1=CC=CN=C1 KBXZFDDFWBCTEY-UHFFFAOYSA-N 0.000 description 1
• CQYDAMLGPFRVKW-UHFFFAOYSA-N n-[3-[4-(3-methyl-4-pyridin-3-yloxyanilino)quinazolin-2-yl]prop-2-ynyl]-2-oxopropanamide Chemical compound C=12C=CC=CC2=NC(C#CCNC(=O)C(=O)C)=NC=1NC(C=C1C)=CC=C1OC1=CC=CN=C1 CQYDAMLGPFRVKW-UHFFFAOYSA-N 0.000 description 1
• NLESLTRIUFKSLV-UHFFFAOYSA-N n-[3-[4-(3-methyl-4-pyridin-3-yloxyanilino)quinazolin-6-yl]prop-2-ynyl]-2-methylsulfonylacetamide Chemical compound CC1=CC(NC=2C3=CC(=CC=C3N=CN=2)C#CCNC(=O)CS(C)(=O)=O)=CC=C1OC1=CC=CN=C1 NLESLTRIUFKSLV-UHFFFAOYSA-N 0.000 description 1
• RTPZLNZEDWMESO-UHFFFAOYSA-N n-[3-[4-(3-methyl-4-pyridin-3-yloxyanilino)quinazolin-6-yl]prop-2-ynyl]butanamide Chemical compound C12=CC(C#CCNC(=O)CCC)=CC=C2N=CN=C1NC(C=C1C)=CC=C1OC1=CC=CN=C1 RTPZLNZEDWMESO-UHFFFAOYSA-N 0.000 description 1
• QKAKSDPZPZYHKK-UHFFFAOYSA-N n-[3-[4-(3-methyl-4-pyridin-3-yloxyanilino)quinazolin-6-yl]prop-2-ynyl]methanesulfonamide Chemical compound CC1=CC(NC=2C3=CC(=CC=C3N=CN=2)C#CCNS(C)(=O)=O)=CC=C1OC1=CC=CN=C1 QKAKSDPZPZYHKK-UHFFFAOYSA-N 0.000 description 1
• MBHSHHSAPSBOKQ-UHFFFAOYSA-N n-[3-[4-(3-methyl-4-pyrimidin-5-yloxyanilino)quinazolin-6-yl]prop-2-ynyl]methanesulfonamide Chemical compound CC1=CC(NC=2C3=CC(=CC=C3N=CN=2)C#CCNS(C)(=O)=O)=CC=C1OC1=CN=CN=C1 MBHSHHSAPSBOKQ-UHFFFAOYSA-N 0.000 description 1
• MXFNETQNSANFNI-UHFFFAOYSA-N n-[3-[4-(4-pyridin-2-yloxyanilino)quinazolin-6-yl]prop-2-ynyl]acetamide Chemical compound C12=CC(C#CCNC(=O)C)=CC=C2N=CN=C1NC(C=C1)=CC=C1OC1=CC=CC=N1 MXFNETQNSANFNI-UHFFFAOYSA-N 0.000 description 1
• JTQDSOZXJBUKBM-UHFFFAOYSA-N n-[3-[4-[3-chloro-4-(6-methylpyridin-3-yl)oxyanilino]-7-methoxyquinazolin-6-yl]prop-2-ynyl]-2-methoxyacetamide Chemical compound N1=CN=C2C=C(OC)C(C#CCNC(=O)COC)=CC2=C1NC(C=C1Cl)=CC=C1OC1=CC=C(C)N=C1 JTQDSOZXJBUKBM-UHFFFAOYSA-N 0.000 description 1
• BLHAJXNJCOSGRL-UHFFFAOYSA-N n-[3-[4-[3-chloro-4-(6-methylpyridin-3-yl)oxyanilino]-7-methoxyquinazolin-6-yl]prop-2-ynyl]acetamide Chemical compound C=12C=C(C#CCNC(C)=O)C(OC)=CC2=NC=NC=1NC(C=C1Cl)=CC=C1OC1=CC=C(C)N=C1 BLHAJXNJCOSGRL-UHFFFAOYSA-N 0.000 description 1
• XVBFOUPNBWDVPO-UHFFFAOYSA-N n-[3-[4-[3-chloro-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-6-yl]prop-2-ynyl]-2,2-difluoroacetamide Chemical compound C1=NC(C)=CC=C1OC(C(=C1)Cl)=CC=C1NC1=NC=NC2=CC=C(C#CCNC(=O)C(F)F)C=C12 XVBFOUPNBWDVPO-UHFFFAOYSA-N 0.000 description 1
• ZTWWDWIZLYYANR-UHFFFAOYSA-N n-[3-[4-[3-chloro-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-6-yl]prop-2-ynyl]-2-(2-hydroxyethylsulfanyl)acetamide Chemical compound C1=NC(C)=CC=C1OC(C(=C1)Cl)=CC=C1NC1=NC=NC2=CC=C(C#CCNC(=O)CSCCO)C=C12 ZTWWDWIZLYYANR-UHFFFAOYSA-N 0.000 description 1
• VGBYYZSZSQYABG-UHFFFAOYSA-N n-[3-[4-[3-chloro-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-6-yl]prop-2-ynyl]-2-(2-methoxyethoxy)acetamide Chemical compound C12=CC(C#CCNC(=O)COCCOC)=CC=C2N=CN=C1NC(C=C1Cl)=CC=C1OC1=CC=C(C)N=C1 VGBYYZSZSQYABG-UHFFFAOYSA-N 0.000 description 1
• FCNRNRPOLFFHKK-UHFFFAOYSA-N n-[3-[4-[3-chloro-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-6-yl]prop-2-ynyl]-2-(dimethylamino)acetamide Chemical compound C12=CC(C#CCNC(=O)CN(C)C)=CC=C2N=CN=C1NC(C=C1Cl)=CC=C1OC1=CC=C(C)N=C1 FCNRNRPOLFFHKK-UHFFFAOYSA-N 0.000 description 1
• OGRRRQTYYRQVKJ-UHFFFAOYSA-N n-[3-[4-[3-chloro-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-6-yl]prop-2-ynyl]-2-(methylamino)acetamide Chemical compound C12=CC(C#CCNC(=O)CNC)=CC=C2N=CN=C1NC(C=C1Cl)=CC=C1OC1=CC=C(C)N=C1 OGRRRQTYYRQVKJ-UHFFFAOYSA-N 0.000 description 1
• SGJOVAXELHYNEA-UHFFFAOYSA-N n-[3-[4-[3-chloro-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-6-yl]prop-2-ynyl]-2-cyanoacetamide Chemical compound C1=NC(C)=CC=C1OC(C(=C1)Cl)=CC=C1NC1=NC=NC2=CC=C(C#CCNC(=O)CC#N)C=C12 SGJOVAXELHYNEA-UHFFFAOYSA-N 0.000 description 1
• LVHFCYBPTAKOIK-UHFFFAOYSA-N n-[3-[4-[3-chloro-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-6-yl]prop-2-ynyl]-2-fluoroacetamide Chemical compound C1=NC(C)=CC=C1OC(C(=C1)Cl)=CC=C1NC1=NC=NC2=CC=C(C#CCNC(=O)CF)C=C12 LVHFCYBPTAKOIK-UHFFFAOYSA-N 0.000 description 1
• OPLICQYLVTXBKX-UHFFFAOYSA-N n-[3-[4-[3-chloro-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-6-yl]prop-2-ynyl]-2-hydroxypropanamide Chemical compound C12=CC(C#CCNC(=O)C(O)C)=CC=C2N=CN=C1NC(C=C1Cl)=CC=C1OC1=CC=C(C)N=C1 OPLICQYLVTXBKX-UHFFFAOYSA-N 0.000 description 1
• KVAQNKFOWZUJGR-UHFFFAOYSA-N n-[3-[4-[3-chloro-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-6-yl]prop-2-ynyl]-2-methoxyacetamide Chemical compound C12=CC(C#CCNC(=O)COC)=CC=C2N=CN=C1NC(C=C1Cl)=CC=C1OC1=CC=C(C)N=C1 KVAQNKFOWZUJGR-UHFFFAOYSA-N 0.000 description 1
• XJHTVHNFQANLSB-UHFFFAOYSA-N n-[3-[4-[3-chloro-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-6-yl]prop-2-ynyl]-2-methoxypropanamide Chemical compound C12=CC(C#CCNC(=O)C(C)OC)=CC=C2N=CN=C1NC(C=C1Cl)=CC=C1OC1=CC=C(C)N=C1 XJHTVHNFQANLSB-UHFFFAOYSA-N 0.000 description 1
• XENQUPGKFLQIRK-UHFFFAOYSA-N n-[3-[4-[3-chloro-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-6-yl]prop-2-ynyl]-2-methylsulfanylacetamide Chemical compound C12=CC(C#CCNC(=O)CSC)=CC=C2N=CN=C1NC(C=C1Cl)=CC=C1OC1=CC=C(C)N=C1 XENQUPGKFLQIRK-UHFFFAOYSA-N 0.000 description 1
• ZRXHTYPPFPWPHE-UHFFFAOYSA-N n-[3-[4-[3-chloro-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-6-yl]prop-2-ynyl]-2-morpholin-4-ylacetamide Chemical compound C1=NC(C)=CC=C1OC(C(=C1)Cl)=CC=C1NC1=NC=NC2=CC=C(C#CCNC(=O)CN3CCOCC3)C=C12 ZRXHTYPPFPWPHE-UHFFFAOYSA-N 0.000 description 1
• DUMRZCLSLYYOLT-UHFFFAOYSA-N n-[3-[4-[3-chloro-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-6-yl]prop-2-ynyl]-2-oxopropanamide Chemical compound C12=CC(C#CCNC(=O)C(=O)C)=CC=C2N=CN=C1NC(C=C1Cl)=CC=C1OC1=CC=C(C)N=C1 DUMRZCLSLYYOLT-UHFFFAOYSA-N 0.000 description 1
• VHMINPZMHMTMCQ-UHFFFAOYSA-N n-[3-[4-[3-chloro-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-6-yl]prop-2-ynyl]methanesulfonamide Chemical compound C1=NC(C)=CC=C1OC(C(=C1)Cl)=CC=C1NC1=NC=NC2=CC=C(C#CCNS(C)(=O)=O)C=C12 VHMINPZMHMTMCQ-UHFFFAOYSA-N 0.000 description 1
• RXWVGHSUJGUFTA-UHFFFAOYSA-N n-[3-[4-[3-chloro-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-6-yl]prop-2-ynyl]propanamide Chemical compound C12=CC(C#CCNC(=O)CC)=CC=C2N=CN=C1NC(C=C1Cl)=CC=C1OC1=CC=C(C)N=C1 RXWVGHSUJGUFTA-UHFFFAOYSA-N 0.000 description 1
• DUYWVEOGXPYJLT-UHFFFAOYSA-N n-[3-[4-[3-fluoro-4-(2-methylpyridin-3-yl)oxyanilino]quinazolin-6-yl]prop-2-ynyl]acetamide Chemical compound C12=CC(C#CCNC(=O)C)=CC=C2N=CN=C1NC(C=C1F)=CC=C1OC1=CC=CN=C1C DUYWVEOGXPYJLT-UHFFFAOYSA-N 0.000 description 1
• RRIOYSLVBRXUGT-UHFFFAOYSA-N n-[3-[4-[3-methyl-4-(2-methylpyridin-3-yl)oxyanilino]quinazolin-6-yl]prop-2-ynyl]-2-oxopropanamide Chemical compound C12=CC(C#CCNC(=O)C(=O)C)=CC=C2N=CN=C1NC(C=C1C)=CC=C1OC1=CC=CN=C1C RRIOYSLVBRXUGT-UHFFFAOYSA-N 0.000 description 1
• LDNVPSSYQSOUII-UHFFFAOYSA-N n-[3-[4-[3-methyl-4-(2-methylpyridin-3-yl)oxyanilino]quinazolin-6-yl]prop-2-ynyl]acetamide Chemical compound C12=CC(C#CCNC(=O)C)=CC=C2N=CN=C1NC(C=C1C)=CC=C1OC1=CC=CN=C1C LDNVPSSYQSOUII-UHFFFAOYSA-N 0.000 description 1
• KZZUHHRXZCQQHD-UHFFFAOYSA-N n-[3-[4-[3-methyl-4-(2-methylpyrimidin-5-yl)oxyanilino]quinazolin-6-yl]prop-2-ynyl]acetamide Chemical compound C12=CC(C#CCNC(=O)C)=CC=C2N=CN=C1NC(C=C1C)=CC=C1OC1=CN=C(C)N=C1 KZZUHHRXZCQQHD-UHFFFAOYSA-N 0.000 description 1
• NWCLAXGKGQGPCT-UHFFFAOYSA-N n-[3-[4-[3-methyl-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-6-yl]prop-2-ynyl]-2-methylsulfanylacetamide Chemical compound C12=CC(C#CCNC(=O)CSC)=CC=C2N=CN=C1NC(C=C1C)=CC=C1OC1=CC=C(C)N=C1 NWCLAXGKGQGPCT-UHFFFAOYSA-N 0.000 description 1
• KBWGSRNXBLMVKR-UHFFFAOYSA-N n-[3-[4-[3-methyl-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-6-yl]prop-2-ynyl]-2-methylsulfonylacetamide Chemical compound C1=NC(C)=CC=C1OC(C(=C1)C)=CC=C1NC1=NC=NC2=CC=C(C#CCNC(=O)CS(C)(=O)=O)C=C12 KBWGSRNXBLMVKR-UHFFFAOYSA-N 0.000 description 1
• YRIKUEDPDQHUSS-UHFFFAOYSA-N n-[3-[4-[3-methyl-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-6-yl]prop-2-ynyl]-2-morpholin-4-ylacetamide Chemical compound C1=NC(C)=CC=C1OC(C(=C1)C)=CC=C1NC1=NC=NC2=CC=C(C#CCNC(=O)CN3CCOCC3)C=C12 YRIKUEDPDQHUSS-UHFFFAOYSA-N 0.000 description 1
• HAZKAGRKQGCHIY-UHFFFAOYSA-N n-[3-[4-[3-methyl-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-6-yl]prop-2-ynyl]butanamide Chemical compound C12=CC(C#CCNC(=O)CCC)=CC=C2N=CN=C1NC(C=C1C)=CC=C1OC1=CC=C(C)N=C1 HAZKAGRKQGCHIY-UHFFFAOYSA-N 0.000 description 1
• VFCAANHVCTVJIP-UHFFFAOYSA-N n-[3-[4-[3-methyl-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-6-yl]prop-2-ynyl]methanesulfonamide Chemical compound C1=NC(C)=CC=C1OC(C(=C1)C)=CC=C1NC1=NC=NC2=CC=C(C#CCNS(C)(=O)=O)C=C12 VFCAANHVCTVJIP-UHFFFAOYSA-N 0.000 description 1
• WXSXUUGOBYKRSY-UHFFFAOYSA-N n-[3-[4-[3-methyl-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-6-yl]prop-2-ynyl]piperazine-1-carboxamide Chemical compound C1=NC(C)=CC=C1OC(C(=C1)C)=CC=C1NC1=NC=NC2=CC=C(C#CCNC(=O)N3CCNCC3)C=C12 WXSXUUGOBYKRSY-UHFFFAOYSA-N 0.000 description 1
• VJADTBNGRPGZPJ-UHFFFAOYSA-N n-[3-[4-[3-methyl-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-6-yl]prop-2-ynyl]propanamide Chemical compound C12=CC(C#CCNC(=O)CC)=CC=C2N=CN=C1NC(C=C1C)=CC=C1OC1=CC=C(C)N=C1 VJADTBNGRPGZPJ-UHFFFAOYSA-N 0.000 description 1
• NLERBAMMPBJCIJ-UHFFFAOYSA-N n-[3-[4-[4-(2-chloropyridin-3-yl)oxy-3-methylanilino]quinazolin-6-yl]prop-2-ynyl]-2-methoxyacetamide Chemical compound C12=CC(C#CCNC(=O)COC)=CC=C2N=CN=C1NC(C=C1C)=CC=C1OC1=CC=CN=C1Cl NLERBAMMPBJCIJ-UHFFFAOYSA-N 0.000 description 1
• QBJAOVGEWOYCFJ-UHFFFAOYSA-N n-[3-[4-[4-(2-chloropyridin-3-yl)oxyanilino]quinazolin-6-yl]prop-2-ynyl]-2-methoxyacetamide Chemical compound C12=CC(C#CCNC(=O)COC)=CC=C2N=CN=C1NC(C=C1)=CC=C1OC1=CC=CN=C1Cl QBJAOVGEWOYCFJ-UHFFFAOYSA-N 0.000 description 1
• YKFXCOILIDECLL-UHFFFAOYSA-N n-[3-[4-[4-(2-chloropyridin-3-yl)oxyanilino]quinazolin-6-yl]prop-2-ynyl]acetamide Chemical compound C12=CC(C#CCNC(=O)C)=CC=C2N=CN=C1NC(C=C1)=CC=C1OC1=CC=CN=C1Cl YKFXCOILIDECLL-UHFFFAOYSA-N 0.000 description 1
• VMOWVRZHGNFSQM-UHFFFAOYSA-N n-[3-[4-[4-(2-methylpyridin-3-yl)oxyanilino]quinazolin-6-yl]prop-2-ynyl]acetamide Chemical compound C12=CC(C#CCNC(=O)C)=CC=C2N=CN=C1NC(C=C1)=CC=C1OC1=CC=CN=C1C VMOWVRZHGNFSQM-UHFFFAOYSA-N 0.000 description 1
• MVZSKRQXMGRUIJ-UHFFFAOYSA-N n-[3-[7-(2-methoxyethoxy)-4-[3-methyl-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-6-yl]prop-2-ynyl]acetamide Chemical compound C=12C=C(C#CCNC(C)=O)C(OCCOC)=CC2=NC=NC=1NC(C=C1C)=CC=C1OC1=CC=C(C)N=C1 MVZSKRQXMGRUIJ-UHFFFAOYSA-N 0.000 description 1
• JJWQWWSJCZNPAL-UHFFFAOYSA-N n-[3-[7-chloro-4-[3-chloro-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-6-yl]prop-2-ynyl]acetamide Chemical compound N1=CN=C2C=C(Cl)C(C#CCNC(=O)C)=CC2=C1NC(C=C1Cl)=CC=C1OC1=CC=C(C)N=C1 JJWQWWSJCZNPAL-UHFFFAOYSA-N 0.000 description 1
• HOHZTZJTMHDZTN-UHFFFAOYSA-N n-[3-[7-chloro-4-[3-methyl-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-6-yl]prop-2-ynyl]acetamide Chemical compound N1=CN=C2C=C(Cl)C(C#CCNC(=O)C)=CC2=C1NC(C=C1C)=CC=C1OC1=CC=C(C)N=C1 HOHZTZJTMHDZTN-UHFFFAOYSA-N 0.000 description 1
• XOCKQBWZNJVROG-UHFFFAOYSA-N n-[3-chloro-4-(6-methylpyridin-3-yl)oxyphenyl]-6-(2-piperidin-3-ylethynyl)quinazolin-4-amine Chemical compound C1=NC(C)=CC=C1OC(C(=C1)Cl)=CC=C1NC1=NC=NC2=CC=C(C#CC3CNCCC3)C=C12 XOCKQBWZNJVROG-UHFFFAOYSA-N 0.000 description 1
• BQVSAAVBRCSSOC-UHFFFAOYSA-N n-[3-chloro-4-(6-methylpyridin-3-yl)oxyphenyl]-6-(2-piperidin-4-ylethynyl)quinazolin-4-amine Chemical compound C1=NC(C)=CC=C1OC(C(=C1)Cl)=CC=C1NC1=NC=NC2=CC=C(C#CC3CCNCC3)C=C12 BQVSAAVBRCSSOC-UHFFFAOYSA-N 0.000 description 1
• FWJJUWUVRRTQFV-UHFFFAOYSA-N n-[3-methyl-4-(2-methylpyridin-3-yl)oxyphenyl]-6-(2-piperidin-3-ylethynyl)quinazolin-4-amine Chemical compound C=1C=C(OC=2C(=NC=CC=2)C)C(C)=CC=1NC(C1=C2)=NC=NC1=CC=C2C#CC1CCCNC1 FWJJUWUVRRTQFV-UHFFFAOYSA-N 0.000 description 1
• JSLXEGOKUDWQIB-UHFFFAOYSA-N n-[3-methyl-4-(2-methylpyrimidin-5-yl)oxyphenyl]-6-(2-piperidin-4-ylethynyl)quinazolin-4-amine Chemical compound C1=NC(C)=NC=C1OC(C(=C1)C)=CC=C1NC1=NC=NC2=CC=C(C#CC3CCNCC3)C=C12 JSLXEGOKUDWQIB-UHFFFAOYSA-N 0.000 description 1
• LQOBGVYQRLJOLW-UHFFFAOYSA-N n-[4-(2-chloropyridin-3-yl)oxy-3-methylphenyl]-6-(2-piperidin-3-ylethynyl)quinazolin-4-amine Chemical compound C=1C=C(OC=2C(=NC=CC=2)Cl)C(C)=CC=1NC(C1=C2)=NC=NC1=CC=C2C#CC1CCCNC1 LQOBGVYQRLJOLW-UHFFFAOYSA-N 0.000 description 1
• UVXXZBLKXBKUQE-UHFFFAOYSA-N n-[4-(2-chloropyridin-3-yl)oxyphenyl]-6-(2-piperidin-3-ylethynyl)quinazolin-4-amine Chemical compound ClC1=NC=CC=C1OC(C=C1)=CC=C1NC1=NC=NC2=CC=C(C#CC3CNCCC3)C=C12 UVXXZBLKXBKUQE-UHFFFAOYSA-N 0.000 description 1
• RZCGOSLUITZUSO-UHFFFAOYSA-N n-[4-(2-chloropyridin-3-yl)oxyphenyl]-6-(2-piperidin-4-ylethynyl)quinazolin-4-amine Chemical compound ClC1=NC=CC=C1OC(C=C1)=CC=C1NC1=NC=NC2=CC=C(C#CC3CCNCC3)C=C12 RZCGOSLUITZUSO-UHFFFAOYSA-N 0.000 description 1
• KRXWYXVZXACXIO-UHFFFAOYSA-N n-[4-(2-methylpyridin-3-yl)oxyphenyl]-6-(2-piperidin-4-ylethynyl)quinazolin-4-amine Chemical compound CC1=NC=CC=C1OC(C=C1)=CC=C1NC1=NC=NC2=CC=C(C#CC3CCNCC3)C=C12 KRXWYXVZXACXIO-UHFFFAOYSA-N 0.000 description 1
• DNKQNGJDYCCDOH-UHFFFAOYSA-N n-[4-[4-(3-chloro-4-pyridin-3-yloxyanilino)quinazolin-6-yl]-1-hydroxybut-3-yn-2-yl]acetamide Chemical compound C12=CC(C#CC(CO)NC(=O)C)=CC=C2N=CN=C1NC(C=C1Cl)=CC=C1OC1=CC=CN=C1 DNKQNGJDYCCDOH-UHFFFAOYSA-N 0.000 description 1
• PWIPPZZVIGNMQW-UHFFFAOYSA-N n-[4-[4-(3-methyl-4-pyridin-3-yloxyanilino)quinazolin-6-yl]but-3-ynyl]-2-methylsulfanylacetamide Chemical compound C12=CC(C#CCCNC(=O)CSC)=CC=C2N=CN=C1NC(C=C1C)=CC=C1OC1=CC=CN=C1 PWIPPZZVIGNMQW-UHFFFAOYSA-N 0.000 description 1
• WQYICQUZPABPGP-UHFFFAOYSA-N n-[4-[4-(3-methyl-4-pyridin-3-yloxyanilino)quinazolin-6-yl]but-3-ynyl]acetamide Chemical compound C12=CC(C#CCCNC(=O)C)=CC=C2N=CN=C1NC(C=C1C)=CC=C1OC1=CC=CN=C1 WQYICQUZPABPGP-UHFFFAOYSA-N 0.000 description 1
• TUZZXLVKAKLTRC-UHFFFAOYSA-N n-[4-[4-[3-chloro-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-6-yl]-1-hydroxybut-3-yn-2-yl]acetamide Chemical compound C12=CC(C#CC(CO)NC(=O)C)=CC=C2N=CN=C1NC(C=C1Cl)=CC=C1OC1=CC=C(C)N=C1 TUZZXLVKAKLTRC-UHFFFAOYSA-N 0.000 description 1
• RBXTXVYGLXQXEK-UHFFFAOYSA-N n-[4-[4-[3-chloro-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-6-yl]-2-methylbut-3-yn-2-yl]-2-hydroxyacetamide Chemical compound C1=NC(C)=CC=C1OC(C(=C1)Cl)=CC=C1NC1=NC=NC2=CC=C(C#CC(C)(C)NC(=O)CO)C=C12 RBXTXVYGLXQXEK-UHFFFAOYSA-N 0.000 description 1
• 125000001624 naphthyl group Chemical group 0.000 description 1
• 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
• 229930014626 natural product Natural products 0.000 description 1
• 208000025402 neoplasm of esophagus Diseases 0.000 description 1
• 230000001537 neural effect Effects 0.000 description 1
• 150000005181 nitrobenzenes Chemical class 0.000 description 1
• 239000012299 nitrogen atmosphere Substances 0.000 description 1
• 229940085033 nolvadex Drugs 0.000 description 1
• 102000037979 non-receptor tyrosine kinases Human genes 0.000 description 1
• 108091008046 non-receptor tyrosine kinases Proteins 0.000 description 1
• 230000000269 nucleophilic effect Effects 0.000 description 1
• 239000002674 ointment Substances 0.000 description 1
• 231100000590 oncogenic Toxicity 0.000 description 1
• 230000002246 oncogenic effect Effects 0.000 description 1
• 230000003287 optical effect Effects 0.000 description 1
• 238000006053 organic reaction Methods 0.000 description 1
• 229960003104 ornithine Drugs 0.000 description 1
• 229940127084 other anti-cancer agent Drugs 0.000 description 1
• 210000001672 ovary Anatomy 0.000 description 1
• 230000002018 overexpression Effects 0.000 description 1
• 125000001715 oxadiazolyl group Chemical group 0.000 description 1
• 125000002971 oxazolyl group Chemical group 0.000 description 1
• 125000003566 oxetanyl group Chemical group 0.000 description 1
• MUJIDPITZJWBSW-UHFFFAOYSA-N palladium(2+) Chemical compound [Pd+2] MUJIDPITZJWBSW-UHFFFAOYSA-N 0.000 description 1
• 210000000496 pancreas Anatomy 0.000 description 1
• 229940014662 pantothenate Drugs 0.000 description 1
• 235000019161 pantothenic acid Nutrition 0.000 description 1
• 239000011713 pantothenic acid Substances 0.000 description 1
• 238000007911 parenteral administration Methods 0.000 description 1
• 108040007629 peroxidase activity proteins Proteins 0.000 description 1
• 235000020030 perry Nutrition 0.000 description 1
• 239000008177 pharmaceutical agent Substances 0.000 description 1
• 230000000144 pharmacologic effect Effects 0.000 description 1
• ZFXLFYCWGIBEFE-UHFFFAOYSA-N phenyl n-[3-[4-[3-chloro-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-6-yl]prop-2-ynyl]carbamate Chemical compound C1=NC(C)=CC=C1OC(C(=C1)Cl)=CC=C1NC1=NC=NC2=CC=C(C#CCNC(=O)OC=3C=CC=CC=3)C=C12 ZFXLFYCWGIBEFE-UHFFFAOYSA-N 0.000 description 1
• RLOWWWKZYUNIDI-UHFFFAOYSA-N phosphinic chloride Chemical compound ClP=O RLOWWWKZYUNIDI-UHFFFAOYSA-N 0.000 description 1
• 125000005541 phosphonamide group Chemical group 0.000 description 1
• 150000003014 phosphoric acid esters Chemical class 0.000 description 1
• 229910052698 phosphorus Inorganic materials 0.000 description 1
• 239000011574 phosphorus Substances 0.000 description 1
• 230000026731 phosphorylation Effects 0.000 description 1
• 238000006366 phosphorylation reaction Methods 0.000 description 1
• DCWXELXMIBXGTH-UHFFFAOYSA-N phosphotyrosine Chemical compound OC(=O)C(N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-UHFFFAOYSA-N 0.000 description 1
• 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
• SIOXPEMLGUPBBT-UHFFFAOYSA-N picolinic acid Chemical compound OC(=O)C1=CC=CC=N1 SIOXPEMLGUPBBT-UHFFFAOYSA-N 0.000 description 1
• 239000006187 pill Substances 0.000 description 1
• 125000004193 piperazinyl group Chemical group 0.000 description 1
• 229910052697 platinum Inorganic materials 0.000 description 1
• BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 1
• 229920001223 polyethylene glycol Polymers 0.000 description 1
• 229920001184 polypeptide Chemical group 0.000 description 1
• 239000011591 potassium Substances 0.000 description 1
• 229910052700 potassium Inorganic materials 0.000 description 1
• 230000003389 potentiating effect Effects 0.000 description 1
• 239000000843 powder Substances 0.000 description 1
• 238000002953 preparative HPLC Methods 0.000 description 1
• 230000002265 prevention Effects 0.000 description 1
• YKPYIPVDTNNYCN-INIZCTEOSA-N prinomastat Chemical compound ONC(=O)[C@H]1C(C)(C)SCCN1S(=O)(=O)C(C=C1)=CC=C1OC1=CC=NC=C1 YKPYIPVDTNNYCN-INIZCTEOSA-N 0.000 description 1
• 229950003608 prinomastat Drugs 0.000 description 1
• 230000008569 process Effects 0.000 description 1
• 108090000765 processed proteins & peptides Chemical group 0.000 description 1
• 102000004196 processed proteins & peptides Human genes 0.000 description 1
• 201000007914 proliferative diabetic retinopathy Diseases 0.000 description 1
• 125000006239 protecting group Chemical group 0.000 description 1
• 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
• 238000000746 purification Methods 0.000 description 1
• 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
• 125000003373 pyrazinyl group Chemical group 0.000 description 1
• 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
• 125000002755 pyrazolinyl group Chemical group 0.000 description 1
• 125000003226 pyrazolyl group Chemical group 0.000 description 1
• 125000002098 pyridazinyl group Chemical group 0.000 description 1
• 125000004076 pyridyl group Chemical group 0.000 description 1
• 125000000714 pyrimidinyl group Chemical group 0.000 description 1
• 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
• 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
• 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
• 230000002285 radioactive effect Effects 0.000 description 1
• 239000000376 reactant Substances 0.000 description 1
• 210000000664 rectum Anatomy 0.000 description 1
• 238000010992 reflux Methods 0.000 description 1
• 230000008844 regulatory mechanism Effects 0.000 description 1
• 208000015347 renal cell adenocarcinoma Diseases 0.000 description 1
• 238000011160 research Methods 0.000 description 1
• 238000012552 review Methods 0.000 description 1
• RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 description 1
• 229960000371 rofecoxib Drugs 0.000 description 1
• YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
• 229960001860 salicylate Drugs 0.000 description 1
• 238000012216 screening Methods 0.000 description 1
• 230000019491 signal transduction Effects 0.000 description 1
• 230000011664 signaling Effects 0.000 description 1
• 230000007781 signaling event Effects 0.000 description 1
• 238000010898 silica gel chromatography Methods 0.000 description 1
• 150000004760 silicates Chemical class 0.000 description 1
• 239000011780 sodium chloride Substances 0.000 description 1
• 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
• 239000008247 solid mixture Substances 0.000 description 1
• 210000000278 spinal cord Anatomy 0.000 description 1
• 201000010132 spinal cord glioma Diseases 0.000 description 1
• 238000010561 standard procedure Methods 0.000 description 1
• 239000008107 starch Substances 0.000 description 1
• 235000019698 starch Nutrition 0.000 description 1
• 239000008174 sterile solution Substances 0.000 description 1
• 210000002784 stomach Anatomy 0.000 description 1
• 150000003440 styrenes Chemical class 0.000 description 1
• 238000006467 substitution reaction Methods 0.000 description 1
• KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
• 239000005720 sucrose Substances 0.000 description 1
• 150000003871 sulfonates Chemical class 0.000 description 1
• 150000003459 sulfonic acid esters Chemical class 0.000 description 1
• 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
• 239000000829 suppository Substances 0.000 description 1
• 239000000375 suspending agent Substances 0.000 description 1
• 238000013268 sustained release Methods 0.000 description 1
• 239000012730 sustained-release form Substances 0.000 description 1
• 239000003765 sweetening agent Substances 0.000 description 1
• 208000024891 symptom Diseases 0.000 description 1
• 238000010189 synthetic method Methods 0.000 description 1
• 239000000454 talc Substances 0.000 description 1
• 229910052623 talc Inorganic materials 0.000 description 1
• 235000012222 talc Nutrition 0.000 description 1
• 229960001603 tamoxifen Drugs 0.000 description 1
• 229940095064 tartrate Drugs 0.000 description 1
• ZINXSRJQNIFDQA-UHFFFAOYSA-N tert-butyl 4-[2-(4-chloroquinazolin-6-yl)ethynyl]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1C#CC1=CC=C(N=CN=C2Cl)C2=C1 ZINXSRJQNIFDQA-UHFFFAOYSA-N 0.000 description 1
• LFKDJXLFVYVEFG-UHFFFAOYSA-N tert-butyl carbamate Chemical compound CC(C)(C)OC(N)=O LFKDJXLFVYVEFG-UHFFFAOYSA-N 0.000 description 1
• DGPCOILGDUFUPC-UHFFFAOYSA-N tert-butyl n-[3-[4-[3-chloro-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-6-yl]prop-2-ynyl]carbamate Chemical compound C1=NC(C)=CC=C1OC(C(=C1)Cl)=CC=C1NC1=NC=NC2=CC=C(C#CCNC(=O)OC(C)(C)C)C=C12 DGPCOILGDUFUPC-UHFFFAOYSA-N 0.000 description 1
• 150000003512 tertiary amines Chemical class 0.000 description 1
• 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
• 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
• 125000005958 tetrahydrothienyl group Chemical group 0.000 description 1
• 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 description 1
• 125000003831 tetrazolyl group Chemical group 0.000 description 1
• 125000005308 thiazepinyl group Chemical group S1N=C(C=CC=C1)* 0.000 description 1
• 125000001544 thienyl group Chemical group 0.000 description 1
• 150000003568 thioethers Chemical class 0.000 description 1
• 150000003573 thiols Chemical class 0.000 description 1
• 210000001685 thyroid gland Anatomy 0.000 description 1
• 208000013076 thyroid tumor Diseases 0.000 description 1
• 230000036962 time dependent Effects 0.000 description 1
• 210000001519 tissue Anatomy 0.000 description 1
• 238000003354 tissue distribution assay Methods 0.000 description 1
• 238000011200 topical administration Methods 0.000 description 1
• 230000000699 topical effect Effects 0.000 description 1
• 239000003053 toxin Substances 0.000 description 1
• 231100000765 toxin Toxicity 0.000 description 1
• 230000026683 transduction Effects 0.000 description 1
• 238000010361 transduction Methods 0.000 description 1
• 230000009466 transformation Effects 0.000 description 1
• 125000004306 triazinyl group Chemical group 0.000 description 1
• 125000001425 triazolyl group Chemical group 0.000 description 1
• IHIXIJGXTJIKRB-UHFFFAOYSA-N trisodium vanadate Chemical compound [Na+].[Na+].[Na+].[O-][V]([O-])([O-])=O IHIXIJGXTJIKRB-UHFFFAOYSA-N 0.000 description 1
• 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 description 1
• 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
• 241000701161 unidentified adenovirus Species 0.000 description 1
• 241000701447 unidentified baculovirus Species 0.000 description 1
• 210000003932 urinary bladder Anatomy 0.000 description 1
• VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
• LNPDTQAFDNKSHK-UHFFFAOYSA-N valdecoxib Chemical compound CC=1ON=C(C=2C=CC=CC=2)C=1C1=CC=C(S(N)(=O)=O)C=C1 LNPDTQAFDNKSHK-UHFFFAOYSA-N 0.000 description 1
• 229960002004 valdecoxib Drugs 0.000 description 1
• 229960003048 vinblastine Drugs 0.000 description 1
• JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
• 229920002554 vinyl polymer Polymers 0.000 description 1
• 210000003905 vulva Anatomy 0.000 description 1